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Chapter 1 
 
 
1.  Glycomics 
 
Glycobiology is the study of the structure, biosynthesis, biology, and evolution 
of saccharides (sugar chains or glycans) present on proteins and lipids, widely 
distributed in nature, and the proteins that recognize them. 
Today, Glycobiology is reaching a broad relevance to many areas of basic 
research, biomedicine, and biotechnology. The field includes the chemistry of 
carbohydrates, the enzymology of glycan formation and degradation, the 
recognition of glycans by specific proteins (lectins and glycosaminoglycan-
binding proteins), glycan roles in complex biological systems, and their 
analysis or manipulation by a variety of techniques (“Essential of 
Glycobiology”, 2nd edition edited by Cold Spring Harbor Laboratory Press; 
2009). Therefore, these studies are aimed to identify a relationship between the 
glycans structures and functionality of the proteins (Raman et al. 2005). 
The interest in this type of study has led to many discoveries, in which it is 
shown that glycans play a decisive role in cell growth and differentiation 
(Hwang et al. 2003), in the cell communication and signalling (Collins et al. 
2004), immune response (Miller 2005), tumor growth and metastasis and 
inflammation (Dube and Bertozzi et al. 2005) etc.. Moreover, it is 
demonstrated that the glycans of specific protein signals or cellular receptors 
are able to modulate the biological process in the development and function of 
multiple physiologic system (as organs and tissues), in part by regulating 
protein-protein and cell-cell interaction (Lowe et al. 2003).  
The glycosylation of proteins is a post-translational event determined by a 
series of processes, which end with the assembling of a chain carbohydrate on 
a specific amino acid. The cellular compartments involved in this process are 
the rough endoplasmic reticulum (RER) and the Golgi apparatus, both holding 
several glycosyl- transferase and glycosidase. 
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The significance of protein glycosylation is manifold. In some cases the 
saccharide units play a structural role, for example, those present at the level of 
the cytoplasmic membrane are involved in cell adhesion. Another possible role 
might be to facilitate the folding of the protein in a particular conformation, 
and allow binding to specific membrane receptors or with the extracellular 
matrix. Although the study of changes in glycan structural composition is of 
great interest and promising, there are still many technical difficulties that 
render it quite cumbersome. Firstly, because the synthesis of glycans depends 
on the activity of a set of several coordinated, and not easily controllable, 
glycosyltransferases and glycosidase, many of which are tissue specific 
(Flukae et al. 2004). To date, it is still impossible to predict the structure(s) of 
the glycosylation side chain(s) based on the protein sequence. 
Second, the cause of the heterogeneity of glycan chains is not only the different 
sequence of single sugars but it is also the bonding between two 
monosaccharide residues, that can have a variety of configurations and 
linkages. There are, in fact, two different stereochemical configurations of 
glycosidic bonds, an alpha linkage and a beta linkage. The only difference 
between the alpha and beta linkages is the orientation of the linked carbon 
atoms. The type of bond that exists between the different sugars greatly 
influences the degree of branching of a chain. 
Therefore, this flexibility and complexity cannot be addressed by using 
conventional analytical approaches as in genomics and proteomics, and as 
consequence, in the “Omics” era, the concept of glycomics has evolved. 
For definition, the terms “Glycome” refers to a repertoire of glycans in a tissue 
or a cell type, and the Glycomics is the study of Glycome.  
Thanks to the progress in mass spectrometry (MS) and oligosaccharide 
analysis technologies, including techniques in derivatization, fluorescent 
labelling, capillary electrophoresis (CE) and high-performance liquid 
chromatography (HPLC), has	  been	  made	  possible. 
Similar to genomics and proteomics approaches, glycomics are supported by 
high-throughput screening in order to identify a panel of distinguishable 
glycomic structures simultaneously. 
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What is glycomic analysis good for? Glycomics should allow investigating on 
the global glycome within body fluids (blood, serum, plasma, seminal fluid, 
urine etc..) or tissues of interest, and this which could eventually lead to 
identify new type of biomarkers for cancer diagnosis, Alzheimer disease, 
cardiovascular diseases, or in the case of the present study,  biomarkers of 
human aging studying specific models of aging.  
Based on their chemical structure, the glycans, are classified in linear and 
branched sugars. Most of the linear sugars linear are glycosaminoglycans 
which contain repeat units of sulfated disaccharides, linked as polysaccharide 
chains to Ser or Thr residues (so called O-linked), to form aggregates of 
proteoglycans. The branched chains instead are classified into two groups: O-
linked and N-linked. In particular, the N-linked glycans are attached to the 
amide group of asparagine (Asn) on the aminoacid sequence of the protein; 
those O-linked, however, are attached to the hydroxyl group of serine (Ser), 
threonine (Thr) or hydroxylysine (LysOH ) (Fig.1) 
 
Figure 1 Chemical diversity of glycans. The directionality of assembling of glycans 
is from non reducing end at the top to the reducing end at the bottom with the arrows 
indicating the extension at the non reducing end. In the case of complex N-linked 
glycans, the common terminal motifs attached to Gal are shown in a dotted box. In the 
N-linked glycans, the assembling starts with the bound between the –OH group of the 
NAcGlc and the NH2 of the asparagine (Asn) Source: “Glycomics: an integrated 
systems approach to structure-function relationships of glycans” Raman R. et al 2005). 
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1.1 N-linked glycans 
 
N-linked oligosaccharides can be subdivided into three main types: high 
mannose, hybrid and complex and they are formed mainly by the combination 
of five types of sugars: mannose (Man), N-acetylglucosamine, (NAcGlc), 
galactose (Gal), fucose (Fuc) and sialic or neuroaminic acid (S).  
In the N-glycan structures, we recognize a “core invariant”, and therefore 
peculiar to all the N-glycan chain, formed by a group of a N-N 
diacetylchitobiose and by a mannosidic core (Fig.2). 
 
 
Figure 2 Invariant core of N-linked chains 
 
The subsequent addition of other sugars, confers variability to the chain, in 
fact, from their combination it possible to generate about 35560 types of 
different tetrasaccharides.  
In most cases, the mannose can be extended in all three positions by a residue 
of N-acetylglucosamine (GlcNAc).  In particular, when GlcNAc is attached to 
the side mannose residues, determines the base of the branched glycans, while, 
when it is attached to the innermost mannose, the GlcNAc is referred to 
“bisecting GlcNac.” and it not requires the addition of more sugars. 
The chain can continue with the attachment of galactose on both ramifications 
and can be concluded with the addition of two sialic acids to form a complete 
biantennary N-glycan (Fig. 3).  
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Figura 3 N-linkage glycan chain . a) biantennary N-glycan (H5N4S2); b) 
biantennary N-glycan with bisection GlcNAc (H5N5S2) 
 
High-mannose type oligosaccharides refer to structures that have two to six 
mannose residues ligated to the internal core mannoses. On the other hand, 
complex oligosaccharides share the internal core mannoses, the outer two α-
mannoses of this structure having N-acetyllactosamines (the disaccharide of 
GlcNAc and galactose) attached. 
These N-acetyllactosamines can be further elongated by the addition of sialic 
or additional N-acetyllactosamines. 
Hybride type oligosaccarides are exactly what their name indicates, they have 
more than three mannose residues and also have N-acetyllactosamine chain 
bound to the α-1-3 linked mannose. Hybrid molececules also usually contain a 
“bisecting” N-acetylglucosamine linked to the innermost mannose of the core 
(Fig.4) 
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Figure 4 The three major types of asparagine.-linked oligosaccharides (N-linked 
glycans). 
 
1.2 N-glycan Biosynthesis 
In contrast to O-glycan synthesis, which initiates and progresses one saccharide 
moiety at a time, N-glycan formation begins in the lumen of the RER with the 
en bloc transfer of a lipid-linked oligosaccharide to asparagine 
cotranslationally (Kornfeld and Kornefeld, 1985; Fukada, 1992). The 
asparagine attached oligosaccharide is then trimmed giving rise to high 
mannose structures. After processing, high mannose structures are modified to 
yeld hybrid and complex oligosaccharides. The biosynthesis of complex N-
linked branching proceeds with the linkage of GlcNAc(s) to the core mannose 
residues. In turn, these bound GlcNAc branches are extended by the sequential 
addition of monosaccharides. The following figure (Fig.5) gives a brief 
overview of this process. 
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1.3 Formation of the Dolichol-Linked Precursor Sugar 
Forming of sugar/lipid precursor begins on the cytosolic side of the RER and is 
completely autonomous from the protein that will be glycosylated 
subsequently. Synthesis of the lipid-linked oligosaccharide is initiated by the 
transfer of GlcNAc-1-phoshate to dolichol pyrophosphate (Dol-P) yielding 
GlcNAc-P-P-Dol.  After the attachment of this GlcNAc, the remaining core 
sugars that are presented by the nucleotide donors, UDP-GlcNAc and GDP-
Figure 5 Branching of mammalian N-glycans 
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Man, become fastened by stepwise addition eventually producing 
Man5GlcNAc2-P-P-Dol. 
 
 
Figure 6 The synthesis of the oligosaccharide precursor. Sugars are  added on one 
at time to the dolichol  carrier molecule. The finished lipid-linked oligosaccharide is 
transfered en bloc to the nascent peptide by oligosaccharylthansferase. The dolichol 
product of this reaction is subsequently recycled. 
This heptasaccharide-lipid intermediate is then translocated to the lumen of the 
RER where it is subjected to further processing.  Although Glc3Man9GlcNAc2-
P-P-Dol is the full grown lipid oligosaccharide found in normal cells, a 
Glc3Man5GlcNAc2-P-P-Dol structure, a glucosylated version of the 
heptasaccharide-lipid mentionated above, is the largest one found in a Dol-P-
Man-deficient lymphoma cell line (Chapman et al. 1979). Taking into account 
the fact that this lipid-linked decasaccharide can also act as a donor substrate in 
protein glycosylation, it may play a role in the biosynthesis of N-glycans.  This 
surrogate route has been termed the “alternative pathway”. 
The assembled precursor molecule is forwarded cotranslationally to asparagine 
residues with the consensus sequence Asn-X-Ser/Thr where X is any amino 
acid except proline or aspartic acid (Marshall, 1972).  
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1.4 Trimming of the Protein-Bound Oligosaccharide 
Initial processing begins with the removal of the three glucose residues by two 
RER-membrane-bound –glucsosidases, α 1,2 glucosidase and α 1,3 
glucosidase (Grinna and Robbins 1978; Elting et al. 1980). Prior to transiting to 
the cis-Golgi, an RER mannosidase cleaves off at least one α-mannosyl residue 
(Bischoff  and Kornfeld, 1983). Additional trimming results in the conversion 
of the oligosaccharide to Man5GlcNAc2 by Golgi α1,2 mannosidase I. N-
acetylglucosaminyltranferase I (GlcNAc-TI) modifies the high mannose 
structure to a hybride glycan as it traverses the medial-Golgi compartment. 
This is a decisive step as it is required for the synthesis of either hybrid or 
complex N-glycans. Cells deficient in GlcNAc-TI are blocked in this pathway 
and can only generate high mannose structures (Li and Kornfeld,  1978; 
Robertson, M.A et al.1978; Tabas  et al. 1978). 
 
1.5 Formation of Hybrid and Complex N-Glycans 
 
After the addition of GlcNAc to the Manα1,3Manβ1,4GlcNAc arm, one of two 
different reactions can occur. The bisecting GlcNAc can be added by 
GlcNAcTIII, thereby, shunting the route toward hybrid structures, or 
alternatively, Golgi α-mannosidase II can remove the two terminal mannoses 
on the Man Manα1,6Manβ1,4GlcNAc arm forming a monoantennary glycan.  
After the action of α-mannosidase II, a second GlcNAc can be added by 
GlcNAc-TII resulting in the conversion of the monoantennary glycan to a 
complex biantennary structure. Additional branches can be generated by 
GlcNAc-TIV and GlcNAC-TV, which add the β1,4 and β1,6 GlcNAc-linked 
residues respectively. Before the glycoprotein leaves the medial-Golgi, its 
branching has already been decided by the medial-Golgi GlcNAc-transferases. 
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Figure 7 The antennae formation of N-glycans. After the transfer of the lipid-linked 
oligosaccharide to asparagine cotranslationally, trimming reactions in the Golgi and 
RER yeld a substrate for GlcNAC-Ti. The action of GlcNac-TII-V determined the 
number of antennae formed. The sugar are symbolized as follows: open circles, 
mannose: black squares, N-acetylglucosamine; shaded triangles, glucose. The 
GlcNAc-transferase I-V are denoted by TI-TV 
After migration to the trans-Golgi, monosaccharides are added one at a time to 
complete the elongation of the antennas. Possible additions include galactose, 
fucose, sialic acid, GlcNAc and others. Moreover, the added sugar residues can 
undergo modifications such as phosphorylation, sulfation and acetylation. 
 
1.6 Microheterogeneity  
The study of a number of purified proteins has revealed that an identical 
protein can carry a variety of oligosaccharides even when produced in the same 
cell (Schachter, H, 1986). While this variance is quite restricted, the reason for 
its occurrence, termed “microheterogeneity” is presently unknown. Variant of a 
glycoprotein, called “glycoforms”, produced in two distinct cell types might 
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arise from differential glycosyltransferase gene expression and may be 
biologically relevant. 
 
1.7 The Bisecting N-Acetylglucosamine of N-Glycans  
An early step in complex and hybrid N-glycan biosynthesis may be initiated by 
GlcNAc-TIII which adds a GlcNAc monosaccharide in β1-4 linkage to the β1-
4 linked mannose of the processed mannose core. Although the function of the 
resulting “bisecting” GlcNAc is not presently known, this modification can 
inhibit completely the action of the other enzymes in subsequent N-glycan 
biosynthesis (α-mannosidase-II, GlcNAc-TII, GlcNAc-TIV, GlcNAcTV, core 
α 1-6-fucosyltransferase) and inhibit partially UDP-Gal:GlcNAc β1-4 
galactosyltransferase (Schachter H., 1986), suggesting a regulatory role in the 
formation and function of complex and hybrid N-glycans. While bisected N-
linked oligosaccharides have not thus far been shown to specifically interact 
with endogenous lectin receptors, altered exogenous lectin binding has been 
reported (Cummings and Kornfeld, 1982; Narasimhan et al. 1986).  
GlcNAc-TIII activity was first described in the hen oviduct (Narasimhan, 
1982) and has subsequently been found in various systems including the rat 
liver during hepatocarcinogenesis (Narasimhan et al. 1988), rat brain 
(Nishikawa et al ,1988), human B lymphocytes (Narasimhan et al, 1988). The 
gene encoding GlcNAc-TIII has been isolated from human (MGAT3) and 
mouse (Mgat3) (Bhaumik et al. 1995).. Expression of Mgat3 RNA appears 
high in mouse brain and kidney tissue. In addition, high levels of GlcNAc-TIII 
activity and bisecting N-glycans have been reported in cells derived from 
patiens with chronic myelogenous leukemia in blast-crisis (Yoshimura et al. 
1995). 
 
1.8 The glycosylation modification of proteins 
 
The glycobiology has led to many innovations in both the biomedical field and 
in basic research. The interest in this field of research is aroused by the fact 
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that the glycans not only influence the protein activity but also by the evidence 
that an aberrant composition of glycan chains is closely related to several 
diseases, such as autoimmune disease and the onset and progression of tumors. 
In physiological condition, the glycans repertoire is involved in mechanism of 
molecular recognition, as in the case of bacterial or viral infections, cell 
adhesion, triggering of inflammatory processes and other events of cellular 
communication (Helenius et al. 2004). 
The changes that can occur on a N-linked glycan chain, can be: an increasing 
in the number of branches; variations in the type of chemical linkage between 
the sugars and the attachment of new sugars within the chain. It is unclear, 
whether these changes are due to a malfunction of the enzymes responsible for 
the formation of the chain or if latters respond to a specific and a new genetic 
signal. 
The changes of the mannosidic core, defined as increase in the number of 
branching constituting the glycan chains, however, are generally associated 
with cancer and autoimmune diseases. 
A model system to understand how the state of glycosylation influences the 
activity of a protein is given by the IgGs. These have a single N-glycosylation 
site, but the IgGs not glycosylated, present in the circulation in rheumatoid 
arthritis, do not retain the ability to activate the complement (Yoshiki et al. 
2006). 
A sugar, instead, whose presence or absence within the glycan chains is 
strongly related to autoimmune diseases and cancer, is the fucose. In the 
complex N-linked glycan chains, the fucose can generally be linked to the first 
NAcGlc residue of dichitobiose or to the NAcGlc residue present on a 
branching, in this last case it forms a specific chain, defined Sialyl Lewis 
x(sLex) (Fig . 8).  
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Figure 8 Sialyl Lewis x(sLex) glycan chain. The glucosidic linkage between NAGlc 
and Fuc is α 1-3 type. 
 
This latter type of branching is present, on numerous proteins, in cases of acute 
and chronic inflammation (Van Dijk et al. 1995). 
The expression of this chain counteracts the progression of pathologies; it has 
been observed in fact, that treatments with soluble sLex may counteract the 
inflammation-induced tissue damage (Mulligan et al. 1993). This is due to the 
fact that this sugar, present on the leukocyte membrane glycoproteins or 
metastatic cells, interacts with E selectins, present at the level of vascular 
endothelial walls. The recognition between sLex and E-selectin allows the 
leukocyte rolling, which precedes the extravasation of leukocytes from the 
blood stream (diapedesis). The increase of molecules with such glycan chain 
prevents the interaction of the endothelial cell receptor (ie the selectin E) with 
the specific ligand situated on the leukocyte membrane (Engers et al. 2000). 
 
Regarding the variations in the type of chemical linkage between the sugars, 
for example, the sialic acids, in case of human glycosylation, can be attached to 
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a terminal galactose either by α 2,6 or α 2,3 glycosidic linkage, showing 
different functionality as a consequence. α2,3-linked N-acetylneuraminic acids 
for example, are specifically  required for formation of sialyl Lewis X 
structures, which have shown to be indicative for metastasis of several types of 
cancer (Isozaki et al. 1998;  Jorgensen, T., et al. 1995) whereas α2,6-linked 
sialic acids show roles in galectin inhibition, thereby promoting cell survival 
(Schultz et al. 2012; et al. 2006). Therefore, in this thesis we investigate the 
either α2,6 or α2,3 sialylation, indicating with (L) and (E), respectively the 
α2,3 glycosid linkage. 
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Chapter 2 
 
2.1 Glycomics and Aging 
 
As previously described, enzymatic glycosylation is the most common co/post-
translational mechanisms of modification of protein involved in a variety of 
processes. Enzymatic glycosylation affects the biological function of the target 
protein: the sugar chains of glycoproteins play an important role in the 
regulation of the interaction between cells and between molecules, such as cell-
cell communication, molecular signalling, antibody function, viral infection 
and bacteria colonization, and regulate the function of hormones and growth 
factors. 
As the biosynthesis of glycan is not template dependent but is controlled by the 
concerned action of diverse enzymes, the sugar chain of glycoprotein is not 
rigorous defined as those of proteins of nucleic acids, but can be altered by the 
physiological or pathophysiological condition of the cell, as cancer, 
inflammation, immune diseases and aging. Though many reports elucidate the 
importance of alteration of glycan structure during development and disease 
[Freeze and Aebi, 2005] scarce information are available on the changes sugar 
moiety of glycoproteins coming during aging. 
 
2.1 N-glycosylation during aging 
It is well know that insulin and IGF-1 participate in growth and aging 
processes. IGF-1 synthesis and secretion is stimulated by Growth hormone 
(GH). IGF-1 is produced by in many tissues, most abundantly in the liver. IGF-
1 mediates mainly actions of GH; it is transported in plasma bound to IGF 
Binding proteins (IGFBP) 1 to 6, but mostly to IGFBP-3. Growth hormone 
synthesis and secretion is influenced by sleep, age, exercise and nutritional 
states and is well documented to decrease with normal aging. Receptors for 
insulin and IGF-1 have similar structure and consist of two subunit linked by 
disulfide bonds that form a tetrameric structure. The receptor result highly 
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glycosilated in the mature and functional form (approximatly for the 25% of 
the final molecular weight; Duronio et al. 1986). Insulin-like growth factor-I 
(IGF-1) is for the most part bound in a ternary complex with IGF-binding 
protein-3 (IGFBP-3) and acid-labile subunit (ALS). The ternary complexes 
regulate IGF availability to the tissues and modulate the endocytosis of IGF-1 
by cells. IGFBP-3 result N-glycosylated at 3 sites, and the modification is 
known to modulate the cell-binding activity of IGFBP-3 (Firth & Baxter, 
1999). ALS present 7 sites of N-glycosylation that can modulate the affinity for 
IGFBP-3. It has been observed also that complete deglycosylation abolished 
the ability of ALS to associate with IGFBP-3 (Janosi et al. 1999). The 
alteration of N-glycosylation of IGF-1 and its binding partners during aging 
have important consequence in terms of cell-availability.  
It has been demonstrated by Sato et al. that the N-linked glycans of 
glycoproteins in the brain of young adults and older rat change with age. 
Glycoproteins in the soluble fraction and in the membrane fraction of various 
portions of brains and spinal cords from 9-week-old rats and 29-month-old rats 
showed marked differences by the age of donors; in particular, glycoproteins 
with an apparent molecular weight of 123K and 115K are increased in old rats. 
These results indicate that the state of glycosylation of some proteins in the 
brain change during aging (Sato et al. 1998). 
Alteration in N-glycosylation is particularly important in serum proteins. 
Immunoglobulin G (IgG) is an exceptional model of glycoprotein because its 
glycosylation has been well described and many important functional effects of 
alternative glycosylation have been designated (Gornik et al. 2012).  
Recently developed high-throughput methods of analysis are now available to 
investigate the N-glycome, or the whole spectrum of N-linked glycans 
associate with proteins soluble in serum and body fluids of large number of 
people; these methods revealed that N-glycome in a way depended to aging. In 
particular, the N-glycome changes seem to be related with the sugar chains 
linked to Asn297 of immunoglobulin G. These aberrant glycosylated IgG can 
activate inflammatory response with ill-starred consequence for the organism. 
In fact, the N-linked sugar chain to Asn297 is located in the Fc portion of IgG 
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and forms the complex biantennary type (Arnold at al. 2007). Antennae are 
concluded by sialic acid and galactose residue (Tsuchiya et al. 1998), while the 
core structure can be replaced by bisecting GlcNAc and/or core-linked fucose.  
The N-linked glycosylation of Asn297 mediate IgG stability and regulate its 
effector functions. In inflammation, autoimmune conditions and aging, the N-
glycosylated Asn297 of IgG undergo characteristic glycosylation changes that 
can be reassumed as (i) reduced presence of galactose and sialic acid in the 
antennae, leaving GlcNAc in terminal positions, (ii) increased expression of 
bisecting GlcNAc and (iii) increased core fucosylation. The first condition is 
the most relevant; in fact the presence/absence of galactose on one or both 
arms of IgG can distinguish three subfamily called IgG-G0 (no galactose), 
IgG-G1 (galactose on one arm) or IgG-G2 (galactose on both arms; Jefferis et 
al., 1990). These modification appear to be associated with several disease as 
inflammation (IgG-G0), lung and ovarian cancers, rheumatoid arthritis and 
primary osteoarthritis.  
A relationship between age and galactosylation of the N-linked chains of IgG 
is reported in a study (Parekh et al. 1988a) that investigated the alterations in 
the level of N-glycosylation of human IgGs during aging. The study involved 
151 healthy individuals of both sex (age 1–70 years). Parekh et al. shown that 
the presence of agalactosyl N-glycans on total serum IgG-G0 decreased from 
birth until 25 years of age and then increased with aging. The relative 
incidence of digalactosyl structures (IgG-G2) showed a concomitant inverse 
relationship with age, whereas the relative incidence of monogalactosyl 
structures (IgG-G1) remained constant. These finding suggest that 
galactosylation of the N-glycans on the human serum IgGs of normal 
individuals is an age-related molecular parameter (Parekh et al. 1988b). 
Successively, a study on 403 individuals from 0 to 85 years old confirmed the 
increased expression of IgG-Go with aging, especially in females (Yamada et 
al. 1997).  
Recently, three groups of researchers studied the age-dependent changes of 
serum N-glycome of large groups of individuals from different part of Europe.  
20	  	  
The first group analysed the age-dependent N-glycomic changes in serum by 
DSA-FACE, in Italian and Belgian individuals (Vanhooren et al. 2007). They 
reported that in people over 60, in both population was there is an important 
increase or core-fucosylated, agalactosylated biantennary N-linked chains with 
or without a bisecting GlcNAc, and a concomitant decrease of core-fucosylated 
digalactosylated structure (Vanhooren et al. 2007, 2008, 2009), expecially in 
IgG and IgG-depleted glycoproteins.  
The Italians’ healthy centenary population, revealed that above 90 years old 
there is an increased agalactosylated structures, whereas in people aged 60-90 
there is a decrease of digalactosylated structures (Vanhooren et al. 2007).  
The second group of researchers established the Leiden Longevity Study which 
consists of of nonagenarian sibling pairs, their offspring, and partners of the 
offspring which serve as control (Ruhaak et al., 2010b). With this cohort group 
they evaluated the association of specific N-glycans with calendar age, but also 
their incidence in offspring, identifying markers for longevity. The analysis of 
tryptic peptides from IgG Fc glycopeptides confirmed the association of 
agalactosylated and monogalactosylated N-linked structures with age. 
Interestingly, in offspring aged less than 60, the level of agalactosylated 
structures with a bisecting GlcNAc was lower than in their partners, suggesting 
that low levels of these markers of aging in young people associate with 
longevity (Ruhaak et al. 2010b). This result was further confirmed by HPLC 
separation of N-glycans from total serum glycoproteins (Ruhaak et al. 2011). 
Two glycan features were found to be more highly expressed in the offspring 
than in controls; also if not fully confirmed, it seems that these markers are 
nonfucosylated biantennary glycans, that also correlated negatively with C-
reactive protein levels which is a marker of inflammation  (Ruhaak et al. 2011).  
The third group investigate the N-glycome of 1008 individuals from the 
Croatian Adriatic island of Vis, by HPLC before and after sialidase treatment. 
The treatment give rise to 33 peaks contained different carbohydrate structures. 
The study confirmed the tendency to age-dependent increase of biantennary 
agalactosylated or mono-galactosylated structures with or without bisecting 
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Glc-NAc and/or core fucosylation, whereas digalactosylated structure finishing 
by sialic acid decrease with age (Knezevic et al. 2009).  
In a genome wide association study, agalactosylated sugar structure presents in 
human blood was discovered to be associated with a single nucleotide 
polymorphism (SNP) located in the intron of the FUT8 locus that encode for 
the fucosyltransferase which mediate the enzymatic transfer of fucose to the 
core of the structure (Lauc et al. 2009, 2010). Linkage with agalactosylated 
biantennary N- linked chains was displayed also by the locus encoding 
estrogen receptor beta (ESR2).  
These findings indicate that the human serum glycome is strongly influenced 
by a genetic basis even though environmental conditions can play a relevant 
role. Moreover, plasma glycan features reflect the age and the healthy status of 
the person and represent a reserve of disease biomarkers.  
 
2.3 Pathogenic effects of altered IgGs 
 
Numerous evidence supports the pathogenic role of IgG-G0 in inflammation 
through different but not mutually exclusive mechanisms. The differential 
glycosylation of IgG-G0 can modulate their effector function via four principal 
mechanisms, which can in turn mediate pathogenic effects: (i) interaction with 
the mannose binding lectin (MBL) for the complement activation; (ii) 
interaction with lectin receptors on the membrane of Antigen Presenting Cells 
(APC); (iii) interaction with Fc receptor on phagocytes and natural killer cells; 
(iv) formation of autoantibody aggregate.  
The age-related accumulation and the differential glycosylation of IgG-G0 can 
contribute to inflammaging, a low-grade pro-inflammatory condition that 
would activate the immune system, exacerbating inflammation. (Dall’Olio et 
al. 2012). A systemic inflammatory condition is common to a variety of 
autoimmune diseases, infectious diseases, cancers and aging. This condition 
alters the glycosylation machinery of antibody-producing cells, resulting in the 
increased expression of agalactosylated and poorly sialylated IgG that, in turn, 
activate different effectors branches of the immune system (complement, APC, 
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phagocytes), resulting in the amplification of inflammatory signals. In this 
scenario, a related expression of sialylated IgG is observed, resulting in 
phagocyte activation.  
The age-related alterations of the N-glycome are not only a strong biomarker 
of biological age, but also the cause of inflammation. Autoimmune diseases, 
cancer and aging are characterized by a low grade inflammatory status 
depending on various stimuli and sources, including the production of 
aberrantly glycosylated IgG that in turn fuel the inflammatory status.  Thus, 
altered N-glycans are both powerful markers of aging and possible contributors 
to its pathogenesis (Dall’Olio et al. 2012) 
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Chapter 3 
 
The Down Syndrome 
 
 
3.1 The Down Syndrome, epidemiological aspects 
 
 
Down syndrome (DS), or trisomy 21, is the most common and know 
chromosomal anomaly, caused by the presence in three copies of chromosome 
21 (Hsa21) or, more rarely, parts of it, following a meiotic non-disjunction 
during ovogenesis. The origin of the supernumerary chromosome 21 is 
maternal in 93% of cases, while in 7% of cases is due to nondisjunction of the 
chromosome of paternal origin. 
In 95% of cases, trisomy 21 is free form, which is the presence of the entire 
surplus Hsa21 not translocated to other chromosomes: in most cases, the 
trisomy 21 is homogeneous, i.e. it is present in all cells analysed, while in 3,5% 
of patients trisomy 21 is in the mosaic, only present in some cells. In 4% of 
cases, the trisomy 21 is due to a translocation of Hsa21 on another 
chromosome (Robertsonian translocation), and finally in 1% of patients 
trisomy 21 is partial. From the clinical point of view the effect is the same, 
while the reproductive consequence (risk of recurrence) for the parental couple 
are related to type of cytogenetic trisomy 21. Therefore for the diagnosis of DS 
is needed the presence of trisomy 21 in association with the clinical picture. 
The estimated incidence of Ds is approximately 1/700- 1/1000 live births, with 
a slight predominance in males (Canfield et al. 2006); the annual number of 
children born with DS appears to be decreasing mainly because of the 
voluntary interruption of pregnancy (VIP); VIP logs show a progressive 
increase in the years of voluntary terminations for DS and It is estimated that 
the percentage of abortions after diagnosis of DS is about 58%. 
The only established risk factor for the DS is advanced maternal age, 
responsible for changes in the process of meiosis (M) of oocytes, in particular 
the meiotic nondisjunction of Hsa21 (Ghosh et al. 2009) during both the phase 
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I (MI) and the phase II (MII), the error rate varies according to maternal age: 
they are lower among mothers aged<19 and >40 years and higher in the 
intermediate group and, in women aged > 40 years, the MII nondisjunction is 
more common (Allen et al. 2009). 
Trisomy 21 results in a high risk of spontaneous abortion and neonatal 
morbidity and mortality: in the period between the time of chorionic villus 
sampling an the period of gestation, the percentage of miscarriages is 43%, 
while between the time of amniocentesis and the term of gestation is 23% 
(Morris et al. 1999). The literature has shown a correlation between maternal 
age and a directly proportional incidence of spontaneous abortion of fetuses 
with DS, with the increasing of the incidence of spontaneous abortions 
associated to the increasing maternal age (from 23% for the mothers at the age 
of 25 years to 45% for those 45 years) (Savva et al. 2006). 
In recent years the quality and life expectancy of patients with DS were 
significantly improved, thanks to continued progress in medical treatment: in 
particular has increased survival in early childhood, following the 
improvement of cardiac surgery, and most people with DS reach over 60 years 
of age; life expectancy for males is greater of about 3.3 years compared 
females; life extension, however, lead to an increase of percentage of diseases 
associated with aging (Glasson et al. 2002). 
 
3.2. The Down Syndrome: cytogenetic aspects 
 
Many studies were designed to identify phenotypic and clinical consequences 
related to the triple gene dosage due to trisomy 21. 
Chromosome 21 has been completely sequenced in the late ‘90s (Hattori et al. 
2000). The genes od Hsa21 so far identified are more than 400 (Gardiner et al. 
2006), 20-50 of which are located at the terminal part of the long arm 
(21q22.2), the so-called Down Syndrome Critical Region (DSCR). Although 
this number is high, it is not an intractable one, and the number of genes that 
are involved in DS is likely to be considerably less than their total number on 
the chromosome. The main question in whether the DS phenotype is 
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determined by only a few genes with a major phenotypic effect or whether the 
phenotype results from the interaction of several genes of modest effect. 
Based on studies in animal models, there is reason to hope that the former 
might be the case. 
Furthermore DS is a disorder of gene dosage in which the genes that are 
involved are normal and their gene products are also normal. The genetic 
abnormality is, therefore, qualitative rather than qualitative and involves the 
production of increased amounts of the products of the genes on chromosome 
21. The simplest expectation was that the degree of overexpression of the 
unbalanced gene would be about 50% (Hattori et al. 2000) and it now seems to 
be generally true (Amano et al. 2004, Dauphinot et al. 2005). This raises the 
question of how such a relatively modest increase in gene expression can have 
such deleterious consequences. The genes in triplicate Hsa21 have an effect on 
the entire integrated genome and affect the expression of many other genes, 
activating or inhibiting, depending on the individual genetic constitution 
(genetic polymorphism): this could explain the variability of phenotypic 
expression and diversity disease in individual patients with DS.  
Finally trisomy for functional non-protein-coding DNA elements might be 
involved in some of the abnormal phenotypes. Comparative analysis of human 
with other vertebrate genomes revealed the presence of conserved regions that 
are not part of the annotated genes (Dermitzakis et al. 2005) .  
The sequence conservation strongly indicates that these elements are 
functional, but the precise function of each one of them is unknown. It is 
however possible that three copies of some of the conserved elements 
contribute to the DS pathology. 
 
3.3 The Down Syndrome: pathogenic aspects 
 
Similar to almost all conditions that result from chromosome imbalance, DS 
affects multiple systems and produces both structural and functional defects 
(Epstein, 2001). In addition, the evolution of the phenotype has a temporal 
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dimension so the issues concerning affected individual, their families and 
society change age with age. 
The clinical diagnosis of DS can be made at birth on the basis of the presence 
of marked hypotonia and a constellation of minor dysmorphic features that 
involve all parts of the body but are especially visible in the craniofacies, hands 
and feet. Nevertheless, these dysmorphic features have little effect on function. 
Anyhow, there are two groups of major congenital abnormalities associated 
with DS, congenital heart disease and several types of gastrointestinal- tract 
obstruction or dysfunction, that can cause morbidity or even death if untreated. 
The recent years considerable progress has been made in understanding and 
explanation of the genetic mechanisms underlying the main phenotypic 
characteristic of DS: developmental abnormalities, susceptibility to certain 
diseases, disability. In particular, through an logarithm to identify non-coding 
RNAs, five microRNAs (miRNAs) have been identified on Hsa21 (Kuhn et al. 
2008, Sethupathy et al. 2007). MicroRNAs regulated the expression of the 
other genes (Bartel, 2004 ) and their role in DS not fully understood. 
 
3.4 Phenotypic variability 
 
Almost every aspect of the phenotype of DS is subject to a high degree of 
variability (Antonarakis and Epstein, 2006 ). No two patients are likely to have 
exactly the same combination of features and none of the minor dysmorphic 
features is present in >80% of the cases. Nevertheless, even when 
superimposed upon familial features, the overall pattern of minor anomalies ad 
distinct, and enables clinical recognition (Epstein, 2001). 
Furthermore, life expectancy of DS Individuals has been rapidly increasing 
over the past 20 years, with a doubling of the median age of death in white 
populations (up to 50 years in 1997), even if environmental effects that result 
from social disparities seem to have deprived various ethnic groups of similar 
benefits (Yang et al. 2002, Leonard et al. 2000). 
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3.5 Congenital Heart defects and Gastrointestinal system Malformations 
 
Approximately half of all children with DS are born a signification congenital 
heart defect (CHD), the most common of which is an atrioventricular septal 
defect (AVSD) (Freeman et al.1998). 
Typically developing children with CHD have been shown to have 
neurocognitive and psychomotor deficits (Malec et al. 1999). For instance, 
school aged children with hypoplastic left heart syndrome have a mean full-
scale IQ of 86, which is below the population normative value, approximately 
one standard deviation (Mahle et al. 2006. Visootsak et al. (2001) have 
documented that there may be possible developmental differences in children 
with DS+AVSD compared to children with DS without CHDs. Issues that 
remain largely unknown in children with DS+AVSD compared to the children 
with DS without CHDs. Issues that remain largely unknown in children with 
DS+AVSD are the magnitude of their cognitive, language, motor, social, and 
adaptive deficits; the patient-related characteristics and perioperative factors 
may influence their neurodevelopmental outcomes and the effects of home 
environmental variables on their development.  
Gastrointestinal defects are second to heart defects among the common serious 
structural birth defects associated with DS (Fabia and Drolette, 1970; Kallen et 
al. 1996) and atresia/stenosis of the small intestine were most common (Cleves 
e al. 2007). 
 
3.6 Immune and Hematopoletic Systems 
 
In addition to the effects on function of the heart and gastrointestinal system, 
trisomy 21 also produces many changes in cellular function (Epstein, 2001). 
Among these, those involving the immune and hematopoietic systems. The 
impact of infection has been greatly reduced with the availability of 
hematopoietic systems. The impact of infection has been greatly reduced with 
the availability of immunizations for various viral and bacterial pathogens 
improved hygiene and antibiotics, however infection is still a major cause of 
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death in DS at any age, and has been suggested that this susceptibility to 
infection depends on abnormal maturation of the thymus and impaired function 
of T lymphocytes (Philip et al. 1986, Murphy et al. 1995), Franceschi et al. 
(1978) found a decreased percentage of T lymphocytes and an increased 
percentage of “null cells” (non-T, non-B lymphocytes), so the immunologic 
defect seems to be a congenital feature of DS, and the antigen overloading 
could worsen the intrinsic immunological derangement and lead to a stress- 
immunodeficiency. In particular subjects with DS showed normal 
responsiveness in allogeneic mixed lymphocyte reactions, but they response to 
phytohemagglutinin and in autologous mixed lymphocyte reactions were 
severely impaired; moreover, the blood concentration of serum thymic factor in 
the majority of DS subjects was much lower than that found in age matched 
healthy controls (Franceschi et al. 1981). 
Furthermore, infants with DS develop acute leukaemia, most commonly acute 
megakaryoblastic (M7) leukemia , with a frequency twenty times higher than 
that in the normal population (Hitzler et al. 2003). This is often preceded by a 
neonatal leukemic reaction (transient myeloproliferative disorder), which 
might be a form of transient leukaemia. A unique non–activating mutation in 
the GATA binding protein 1 (GATA1) gene (on the X chromosome) has been 
found in association with both the leukaemia and the leukemic reaction (Hitzler 
et al.2003, Wechsler et al. 2002), and children with DS seem to have  a better 
prognosis and require less chemotherapy than children without DS (Gamis, 
2005). 
 
3.7 Central Nervous System 
 
The trisomic state hits the central Nervous Systems (CNS), which results 
vulnerable throughout life. The brain is grossly normal with the exception of 
some degree of hypoplasia of the cerebellum (Aylward et al. 1997). 
Nevertheless, perhaps the most frequent sign of DS is a central hypotonia, 
followed by delayed cognitive abilities in adulthood and the development of 
Alzheimer’s disease (AD) in later years (Busciglio et al. 2002). 
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The literature shows that the 8-13,6% of individuals with DS develop epilepsy, 
(Pueschel et al.1991; Goldberg-Dtern et al. 2001), that cognitive development 
is in the range of mental retardation (usually grade medium-mild) (Brown et 
al.1990) and that there is a frequency of autistic disorder, 7-11% (Knit et 
al.1999; Kroger and Nelson, 2006). 
In general, the stages of development follow the normal sequence, with a 
particular deficit in the production of language (Chapman et al. 1998), in 
childhood have been reported behavioural disorders conduct (5,4%) or 
aggressive behaviour (6,5%) while it can take as an adult major depression 
(6,1%) or aggressive behaviour (6,15) (Myers and Pueschel, 1991). 
All domains of intellectual function do not have uniformly cognitive 
impairment, and there are both strengths and weaknesses in intellectual ability 
(Nedel 2003). The forms of learning that depend on the hippocampus are 
particularly affected, and there is also evidence for impairment of prefrontal 
cortex and cerebellar functions (Nedel 2003). Speech and articulation are 
particularly affected. Numerous anatomical, biochemical and physiological 
studies have shed little light on the basis for cognitive impairment (Epstein, 
2001). Several years ago have been observed morphological abnormalities of 
the dendritic spines, which are the sites of synapse formation, and this 
originally non-specific finding has been considerable reappraised with the 
discovery of similar abnormalities in the brains of Ts65Dn mice (Belichencko 
et al. 2005). Hippocampal neurons in TsD65D brains also exhibit major 
abnormalities in long-term potentiation (LPTD) and long-term depression 
(LTD), which are electrophysiological phenomena associated with learning and 
memory (Kleschevnikov et al. 2004). The finding of similar abnormalities in 
the brain of people with DS might increase the understanding of the basis of 
cognitive impairment in DS and might provide potential therapeutic targets 
(Antonarakis and Epstein, 2006). Moreover, another abnormality in the 
Ts65Dn mouse brain might be directly relevant to humans, i.e. the progressive 
loss and atrophy of cholinergic neurons in the basal forebrain (Salehi et al. 
2006; Granholm et al. 200), a neuronal population that is particularly 
vulnerable in AD. 
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The diagnosis of dementia in DS requires an understanding of baseline 
cognitive and emotional functioning in the disorder. For example, most healthy 
people with DS prior to the onset of dementia would score below detectable 
levels on the Mini Mental State Examination, a screening test for dementia 
administered to risk individuals in the general population. In the child and adult 
with DS, measures od IQ, general cognitive functioning, and mental age are at 
least two standard deviations below the norm and these global anchor measures 
appear to exceed performance in language, phonology, and memory (Miller, 
1988). Auditory verbal memory is selectively impaired beyond global baseline 
functioning (Varnhagen et al. 1987). These findings can become confounding 
factors for the determination of dementia in DS and have led to a consensus 
statement for testing individuals at risk (Aylward et al. 1997). One alternative 
to traditional direct testing of adults with developmental disabilities involves 
looking to sources other than the patient for information (Burt et al. 1998). 
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Aim of the study 
 
Previous studies, performed in the laboratory where my thesis was elaborated, 
demonstrated that there is a linkage between successful/unsuccesful ageing and 
alterations of serum glycome, suggesting that measurements of the log ratio of 
two glycans (NGA2F and NA2F), named GlycoAge test  (Vanhooren et al. 
2007, 2010), could provide a non invasive biomarker of aging. As discussed in 
the previous chapters, Down syndrome (DS) is a genetic disorder in which 
multiple major aspects of senescent phenotype occur much earlier than in 
healthy age-matched subjects and has been often defined as an accelerated 
aging syndrome.  
Therefore the questions this study was aimed at finding a possible answer are: 
- Is DS characterized by a specific N-glycomic signature? Data will be 
presented comparing the plasma N-glycome of patients affected by DS with 
age- and sex matched non-affected controls, represented by their siblings 
(DSS).  Since DS and DSS subjects share or have shared for many years the 
same environment, this comparison will be informative on the effect of the 
disease on the plasma N-glycosylation changes. 
- What is the contribution of ageing within DS? Data will be presented 
comparing DS of different age, as well as DS with their mothers (DSM) who 
also shared a genetic background. 
- What is the contribution of epigenetic or environmental factors? Data will be 
presented comparing DS singletons (DSW) with unrelated age-sex matched 
controls. 
Glycomic analysis has been performed on blood serum by means of two 
different techniques:  
i. a  high-sensitive protocol based on a MALDI-TOF-MS approach. A 
special focus on α2-3 and α2-6 specific linkage of sialic acids of the 
plasma N-glycome will be made;  
ii.  the DSA-FACE technology, in order to validate and go deeper the first 
approach. 
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Material and Methods 
 
1. Study design 
 
The rationale of this study was to compare the plasma N-glycome of patients 
affected by Down Syndrome (DS) with age and sex matched non-affected 
controls, represented by their siblings (DSS), in order to assess if Down 
Syndrome is characterized by a specific N-glycomic pattern and to study 
glycosylation changes of human blood proteins which are associated with 
Down syndrome. 
Since DS and DSS subjects share or have shared for many years the same 
environmental factors, this family-based study model is particularly useful to 
investigate the effect of disease on the plasma N-glycosylation changes, while 
reducing the between-group difference in familial and epigenetic variables. 
Moreover, we enrolled a group of DS singletons, (DSW) i.e without 
brothers/sisters, that have a different age respect the DS and DSS group. This 
group is important not only to investigate the effect of aging on the plasma N-
glycans changes within the disease but also to validate the specific N-glycomic 
signature of disease, reducing all other factors (epigenetic, aging, genetic, etc..) 
that could impact and influence the pattern discrimination. 
Lastly, in order to investigate if the N-glycans changes that occur in DS were 
able to reveal an accelerated aging in DS patients, we enrolled, when it was 
possible, the mothers (DSM) of the DS and DSS, representing the non-affected 
control group with a different chronological age respect to DS. 
2. Samples 
 
The study population is represented by the following three groups of subjects 
(158 subjects in total) i) 75 subjects affected with Down Syndrome (DS), in 
particular, in this group, are present two subgroups: a. the first, is constituted 
by 38 Down syndrome subjects (DS) with a mean age of 27.2 years, belonging 
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to families where it is present also their respective brother/sister with similar 
age; b. the second, is constituted by 37 Down syndrome patients, singletons 
(DSW); with a mean age of 38.5 years, i.e without brothers/sisters, and 
characterized to be older than DS. ii) 38 age- and sex-matched non-affected 
controls (DSS) represented by the siblings of DS patients, with a mean age of 
30.9 years; iii) 45 subjects represented by the mothers (DSM) of the DS and 
DSS, with a mean age of 57.1 years.  
We recruited in total 35 complete family composed by the triad DS-DSS-DSM, 
3 families where are only present the brother/sister of the DS; 37 DS subjects 
singletons, i.e, without brother/sisters. In this last group are present 27 DS 
without siblings and mothers, and 10 DS without siblings but their mother have 
been recruited. 
 After informed consent obtained from the family or the guardians, plasma 
samples were collected from EDTA-treated blood of all subjects. DS diagnosis 
was confirmed by karyotype. In the study were excluded subjects with an acute 
pathology in place; patients with hepatic, renal, or cardiac deficiency; patients 
who have taken two months before the recruitment multivitamin or anti-
inflammatory drugs. The study was approved by the local ethics committee. 
For this study we applied two different N-glycomics approaches:  
- first, in order to study the complete plasma N-glycome and the glycosylation 
changes of human blood proteins which are associated with Down syndrome, 
we applied a high-sensitive protocol based on a MALDI-TOF-MS approach. 
Thanks to the specificity of this protocol particular attention was focused on 
the linkage specificity α2-3 and α2-6 of sialic acids of the plasma N-glycome.  
- second, we used, on the same samples, a second approach based on the DSA-
FACE technology in order to validate and to deep with the first approach the 
plasma DSA-FACE fingerprinting and the derived variables, as the GlycoAge 
test. 
3. Plasma N-Glycome with MALDI-TOF/MS approach. 
The analysis of the samples, performed with the MALDI-TOF/MS approach, 
were conducted during my PhD visiting research at the laboratory of Glycomic 
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and Glycoproteomics in Leiden (Netherlands). This new MALDI-TOF/MS 
protocol is in paper submission. 
3.1 Enzymatic N-glycan release 
N-glycans were released from the plasma of all subjects. 10 µL of plasma was 
denatured by adding 20 µL 2% sodium dodecyl sulphate (SDS) and incubating 
for 10 minutes at 60°C. The release step was subsequently performed by 
adding 20 µl release mixture containing 2% Nonidet P-40 (NP-40) and 0.5 mU 
recombinant peptide-N-glycosidase F (PNGase F) in 2.5x PBS and incubating 
overnight at 37°C. 
3.2 Ethyl esterification of unpurified PNGase F released plasma N-
glycome samples 
A robust, high-throughput MALDI-TOF-MS method for profiling human 
plasma N-glycans with linkage-specific derivatization of sialic acid residues 
was assessed according as the described in Reiding et al, 2013 (submitted). 
Reaction conditions were optimized to achieve ethyl-esterification at the 
carboxyl group of 2,6-linked sialic acid residues, whilst 2,3-linked sialic acid 
underwent lactone formation. (Fig.9). 
Shortly, for each sample, 1 µL released plasma N-glycome (approximating 14 
µg of plasma protein) was added to 20 µL of ethanol, containing reagent 
1h 37°C!
1h 37°C!
EDC/HOBt!
Ethanol!
EDC/HOBt!
Ethanol!
α2,6%
+28$Da$
α2,3%
'18$Da$
Figure 9. Linkage-specific ethyl esterification of sialic acid 
residues in released plasma N-glycans 
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combinations 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) with 
hydroxybenzotriazole (HOBt), each one at the final concentration of 0.25 M. 
All the samples, distributed in 96-wells PCR plate format, were incubated 1h at 
60°C, sealing the plate to prevent evaporation.  
3.3. Hydrophilic interaction liquid chromatography (HILIC)-SPE of 
unpurified N-glycans 
A sample clean-up was deemed necessary for enrichment and purification of 
the glycans from the reaction mixture, and we chose for hydrophilic interaction 
liquid chromatography (HILIC)-SPE using cotton as stationary phase, as 
described in Selman  et al.2011. 
Hereafter, 20 µL acetonitrile (ACN) was added and all samples were incubated 
15 min at 20°C before proceeding with glycan enrichment and analysis by 
MALDI-TOF-MS. To perform HILIC SPE, 200 µg of cotton was inserted into 
tips, washed with 3x 20 µL Milli-Q water (MQ) and 3x 20 µL 85% ACN, 
loaded with sample by pipetting 20x into the reaction mixture, washed with 3x 
20 µL 85% ACN 1% trifluoroacetic acid (TFA,) 3x 20 µL 85% ACN, and 
eluted with 10 µL MQ. Careful pipetting was necessary to prevent clotting of 
the tips. 
For MALDI-TOF-MS analysis, 1 µL of glycan sample purified by cotton 
HILIC SPE was spotted on a MTP AnchorChip 800/384 TF MALDI target 
(Bruker Daltonik, Bremen, Germany), mixed on plate with 1 µL 2.5-
dihydroxybenzoic acid (2.5-DHB) (5 mg/mL) in 50% ACN and 1 mM NaOH, 
and left to dry. The matrix crystals were homogenized by adding 0.2 µL 
ethanol, for a rapid recrystallization. 
3.4 Processing of MALDI-TOF-MS data  
Analysis was performed by UltraFlextreme MALDI-TOF/TOF-MS (Bruker 
Daltonik, Bremen, Germany) in reflectron positive (RP) ion mode, using 
Flexcontrol 3.4 Build 119. Before sample measurement, the spectra were 
calibrated on the known masses of a peptide calibration standard (Bruker 
Daltonik, Bremen, Germany). All samples were ionized by a smartbeam-II 
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laser, and accelerated with 25 kV after 140 ns delayed extraction. . For each 
spectrum, 20000 laser shots were accumulated at a laser frequency of 2000 Hz, 
using a complete sample random walk with 200 shots per raster spot. Using 
flexAnalysis v3.3 build 65 (Bruker Daltonik), the acquired MALDI-TOF-MS 
spectra were internally recalibrated using varying calibration masses and the 
masses were calculated as [M+Na]+. Abbreviations used for glycan annotation 
are: hexose (H), N-acetylhexosamine (N), fucose (F) and N-acetylneuraminic 
acid with unspecified linkage (S), with the accompanying number indicating 
the number of residues. Glycan signals were integrated, normalized to the sum 
of intensities and the relative signals calculated. Starting from 10 ul of human 
plasma, glycan profiles were achieved allowing the differentiation of 114 
glycan species (Fig.10) 
 
Figure 10 RP MALDI-TOF-MS spectrum after applying EDC+HOBt ethyl 
esterification protocol for plasma N-glycome analysis. A) Complete spectrum 
overview showing relative intensities from 1000 Da to 5000 Da.. B) High range 
spectrum from 3800 Da to 5000 Da showing glycan derivable masses up to 4727.640 
Da. While the mass precision makes most compositional assignments likely, the 
structures shown are based on literature and may not reflect the actual sample. 
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Plasma profiles studied using the ethyl esterification protocol showed glycans 
[M+Na]+ ranging in mass from 1257.423 Da (H5N2) to 4727.640 Da 
(H10N9F1 with four lactonized sialic acids (abbreviated as L) indicating α2,3-
linkage). 
Reproducibility of human plasma N-glycome profiling employing 1 h 37°C 
EDC + HOBt ethyl esterification was demonstrated by multiple repeat analyses 
on three different days on 24 samples controls. 
 Average relative intensity values for the highest peak (H5N4 with two 
esterified sialic acids (abbreviated as E) indicating α2,6-linkage) were around 
54.7% (SD ± 2.3%) across all measurements, with the CV averaging around 
3.8%. (Fig. 11) 
 
 
Figure 11 Reproducibility assay of 1h 37°C EDC + HOBt ethyl esterification. 24 
samples originating from a common stock of plasma were independently released by 
PNGase F, ethyl esterified, purified by HILIC SPE, crystallized with matrix, 
recrystallized with ethanol, and analyzed by RP MALDI-TOF-MS. The experiment 
was performed three times on separate days, indicated as experiment 1-3. The graph 
shows the average relative intensities observed (normalized to the sum of intensities), 
with error bars for standard deviation 
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For our analysis, we used all peaks, that had signal intensity higher than 
background noise, selecting 98 peaks N-glycans. The complete list of 98 N-
glycans features, with the assigned composition is indicated in the Table 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  Complete list of the total 98  neutral N-glycans  of plasma N-glycome 
detected using ethyl esterification protocol. In the table is indicated  for each N-
glycans feature the corrisponding code peak, into the MALDI spectrum, the 
composition and the m/z value.  
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4. Plasma N-Glycome with DSA-FACE approach 
 
The department for Molecular Biomedical Research of Ghent University 
(Belgium) developed an ultra-sensitive technique to profile and sequence N-
linked glycans using standard DNA-sequencing equipment (Callewaert et al. 
2001; Laroy et al. 2006). This technology is named  “DNA Sequencer 
Adapted-Fluorophore Assisted Carbohydrate Electrophoresis” (DSA-FACE), 
thanks to which it possible to obtain an accurate fingerprint of the glycan 
mixture (serum or plasma).  Subsequently, Valerie Vanhooren and Chitty Chen 
of the Ghent University, adapted DSA-FACE technique for the study of human 
aging, publishing several works in collaboration with the laboratory, directed 
by Prof. Claudio Franceschi (Vanhooren V. et al, 2007 and 2010). 
During my PhD period I set up the same technique in our laboratory, and I 
applied the protocol to analyse the samples of this study. A schematic 
visualization of the N-glycan analysis using DSA-FACE technique is 
illustrated in figure 12.  
 
Figure 12. Schematic visualization of the N-glycans analyis via DSA_FACE 
techique. (Image was taken from VanHooren et al. 2008) 
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 4.1 Preparing N-glycans 
The total protein pool present in 2 ul of plasma is incubated with 2 ul of Milli-
Q water (MQ) and 2 ul of denaturing buffer (5% SDS in 10 mM NH4HCO3) in 
a 96-well plate, for the protein denaturation. The plate is sealed and incubated  
for 5 min at 95 °C and then cool down for 15 min at 4°C. The N-glycans are 
cleaved  by enzymatic digestion with 3 µl of a release mixture containing 
3.33% Nonidet P-40 (NP-40) and 6.6 units of recombinant peptide-N-
glycosidase F (PNGase F) (New England Biolabs) in denaturing buffer and 
incubating for 3 h at 37 °C.  The reaction is stopped by adding 100 µl of water. 
4.2 Labelling of released plasma N-glycans 
The released plasma N-glycan were then derivatized with the fluorophore  8-
amino-1,3,6-pyrenetrisulfonic acid (APTS).  Briefly, 6 µl of released N-
glycans mixture are dried completely into a new plate, at 60 °C for 1 h, and 
then, on the dried pellet were added 2 µl of APTS labeling buffer, constituted 
by a 1:1 mixture of 20 mM APTS in 1.2 M citric acid and 1M NaCNBH3 in 
Dimethylsulfoxide (DMSO). The labelling reaction is followed by an overnight 
incubation at 37 °C, sealing the plate to prevent the evaporation, and then 
stopped by adding 200 µl of water for well. 
4.3 Desialylation of labelled plasma N-glycans. 
Since most of the plasma/serum glycans terminate with sialic acids, which 
contain negative charges, their removal, before of the electrophoretic run, 
makes the final profiling clearer. In this step, the N-glycans were desialylated 
by adding into 2 µl of APTS labelled sugars, 0.25 µl 100 mM NH4AC, 0.2 µl 
neuraminidase of Arthrobacter ureafaciens (Roche) and 2.55  µl water, with a 
overnight incubation at 37°C. The desialylation reaction was stopped with 160 
µl of water added in each wells. 
4.4. Separating N-glycans with DNA-sequencer and data processing 
10 µl of APTS labeled and digested glycans were analysed using a capillary 
electrophoresis (CE)-based ABI 3130 DNA sequencer (Applied Biosystem) 
equipped with a standard 36-cm capillary array filled with the POP-7 
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polyacrylamide linear polymer. The data was processed with the GeneMapper 
software (Applied Biosystem) using the factory-provided settings for amplified 
fragment length polymorphism (AFLP) analysis.  
Each structure of N-glycans, identified with a peak into a typical DNA 
sequencing electropherogram was numerically described by normalizing its 
height to the sum of the heights of all peaks. 
4.5 Plasma N-glycan profiling  
10-12 peaks generally constitute the characteristic DSA-FACE N-glycome 
profiling for total plasma/serum glycoproteins, and each one identifies a 
specific N-glycan structure. Compared with mass spectrometric methods, this 
protocol resolves isobaric glycan stereoisomers, but the possibilities of 
characterization of an unknown compound are limited to the use of standars for 
comigration and to enzymatic degradations (Klein A., Adv Clin Chem. 2008) 
Indeed, the structures of these peaks had been characterized previously by 
Laroy W. et al., Nat Protoc, 2006, using specific exoglycosidases. The 
structures of the N-glycans peaks are shown in figure 13. In particular Peak 1 is 
an agalactosylated,core-α-1,6-fucosylated biantennary glycan (NGA2F), peak 
2 is an agalactosylated, core-α-1,6-fucosylated bisecting biantennary 
(NGA2FB), peaks 3 and 4 are mono galactosylated, core-α-1,6-fucosylated 
biantennary (NG1A2F), peak 5 is a bigalactosylated, biantennary glycan 
(NA2), peak 6 is a bigalactosylated, core- α-1,6-fucosylated biantennary 
(NA2F), peak 7 is a bigalactosylated, core-α-1,6-fucosylated bisecting 
biantennary (NA2FB), peak 8 is a trigalactosylated, tri-antennary (NA3), peak 
9 is a branching α-1,3-fucosylated trigalactosylated tri-antennary (NA3F(b)), 
peak 9’ is a core-1,6 fucosylated trigalactosylated tri-antennary (NA3F), peak 
10 is a tetra-galactosylated, tetra antennary (NA4). 
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Figure 13 A typical desialylated N-glycan profile for total serum/plasma proteins, 
For each peak is indicated the corrisponding N-glycan structure. The symbols used in 
the structural formulas are: n N-acetyl-glucosamine (GlcNAc); ο β-linked galactose; Δ 
α -1,3/6-linked fucose;   α/β-linked mannose. 
 
 
5. Statistical Analysis 
 
The pattern  of plasma N-glycome of Down Syndrome, both for the analysis 
performed with MALDI-TOF/MS and with DSA-FACE approach, was 
investigated by partial least squares discriminant analysis (PLS-DA), which is 
a supervised multivariate data analysis method that is part of the SIMCA 
software (Umetrics). The results from the PLS-DA analysis were visualized by 
plotting two principal components of the model against each other in a 
scatterplot. The plot illustrates the degree of separation explained by the 
components. Each point in the scatterplot represents a subject. Each principal 
component receives a Q2 value, which describes the statistical significance and 
the predictive power of that component. 
The PLS-DA allows us to plot the structures according to their importance for 
separating the groups. Structures receive a variable of importance (VIP) value. 
Values > 1 indicate that the structure is involved above average in the 
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separation of groups.. To assess the individual discriminant ability of each 
component of the signature, we applied the non parametric Wilcoxon Rank 
sum tests among the compared groups (SPSS).  
Results were corrected for multiple comparisons by a Benjiamin Hoocberg 
correction (R free online software). A P value <0.05 was considered significant 
after the FDR (false discovered rate) correction. 
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Results 
 
4. Samples 
 
In this study we analysed in total 158 samples, constituted by the following 
three groups of subjects (see Table 2):  
i) 75 total patients affected by Down Syndrome (DS), constituted by 2 
subgroups: 38 Down syndrome subjects (DS) with a mean age of 27.2 years, 
belonging to families where it is present also their respective brother/sister 
with similar age; b. 37 Down syndrome patients, singletons (DSW); with a 
mean age of 38.5 years, i.e without brothers/sisters, and characterized to be 
older than DS. 
ii)  38 non-affected controls represented by the siblings of 38 DS patients, with 
a mean age of 30.0 years (range:11-65);  
iii) 45 subjects represented by the mothers (DSM) of the DS and DSS, with a 
mean age of 56.9 years (range:12-76).  
These subjects are distributed this way: 35 complete families in which is 
present the triad DS,DSS and DSM; 3 families where only the DS subject and 
his/her brother/sister have been recruited; 37 DS Singletons (DSW), i.e 
subjects without brothers/sisters. In this group are present 27 DS without 
siblings and mothers, and 10 DS without siblings but their mother have been 
recruited.  
Status Group 
Total Down Syndrome Patients 
(DS) 
N=75 
Non -affected 
Siblings (DSS) 
 
N=38 
Mothers 
(DSM) 
 
N=45 DS 
N=38 
DS 
“Singletons”(DSW) 
N=37 
Males (N, %) 21 18 11 - 
Females (N,%) 17 19 27 45 
Age both sex: mean 
±SD, years (Age 
Range) 
27.2 ± 11.1 
(10-58) 
38.5± 14.5 
(13-66) 
30.9 ± 10.9 
(12-52) 
57.1 ± 9.6 
(41-83) 
P valuea <0.0011 0.152
2 
0.0153 
<0.0014 
<0.0015 !  
a. A parametric T-test was performed to compare Ds and DSW with the other groups. 
1=DSvsDSW; 2=DSvsDSS; 3=DSWvsDSS;4=DSvsDSM;5=DSWvsDSM. 
Table 2: Sample distribution and general characteristics of study participants 
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5. Plasma N-glycome analysis with MALDI-TOF/MS technology 
 
As described previously in Material and Method, using MALDI-TOF mass 
spectrometry we detected a set of 98 plasma N-glycans that was chosen for a 
quantitative analysis. Their intensities were normalized to the sum of all those 
peaks. 
Fig 14 presents an example of three representative N-glycan spectrum of a 
complete family, composed by DS, DSS and their DSM. We quantified 98 
glycan ions (see Table 1 in the Material method for the completed list) and 
confirmed assigned glycan structures by MSn  sequencing.  
 
 
In order to identify a specific N-glycomic signature of the Down syndrome, we 
directed our analysis in the identification of the plasma N-glycans that were 
Figure 14 Representative plasma N-glycan profile of a triad family composed by 
DS, DSS, DSM. All plasma N-glycan (see Table 1 in Material and Method ) were 
confirmed by MSn fragmentation. For clarity of the images, only a selection of 
glycans is shown. GlcNAc (f), mannose (F), Gal (E), NeuNAc (), and Fuc (Š) 
moieties are indicated 
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able to discriminate the group of DS from those of the respective non-affected 
DSS, by focusing, initially, on the complete pairs DS-DSS. This comparison 
should be representative of the effect of disease on the plasma N-glycosylation 
changes. 
Therefore, we extracted the N-glycan structures with potential discriminative 
power, performing a partial lest squares discriminant analysis (PLS-DA)  (see 
the statistical analysis in Materials and Method for details) using as variables 
for the model only the 98 totals N-glycans (the variables as gender and age 
were not considered into the analysis).  
The multivariate discriminant analysis (see the statistical analysis in Materials 
and Method for details) performed comparing DS and DSS is shown in the 
PLS-DA scatterplot (Fig 15 )  
PLS-DA, DS vs DSS 
Colored according to classes 
t [ 2
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R2X[1] = 0,129                R2X[2] = 0,073                Ellipse: Hotelling's T2 (95%)  
DS 
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SIMCA 13.0 - 21-01-2014 16:17:44 (UTC+1)   
Fig15. Scatterplots of the PLS-DA models assessed comparing DS with DSS. The 
plot illustrates the degree of separation between groups.  Each plot represent a sample 
where, in blue are coloured the DS and in green their DSS. The triangle indicate the 
males, the square the females. The horizontal scale refers to the first component (t[1]), 
whereas the vertical scale refers to second component (t[2]).  
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The analysis revealed an evident clustering of the two groups, in particular a 
large part of the variation within the data (72% R2Ycum) could be explained 
by the two-component PLS-DA model and a good prediction ability Q2(cum) 
of 85% was achieved. The corresponding loading plot of the PLS-DA model is 
shown in Fig 16. 
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Fig.16 Loading plot of the PLS-DA models assessed comparing DS with DSS. In 
this figure is shown the loading plot of the PLS-DA model based on MALDI-TOF/MS 
data with DS and DSS as class identities, which indicates the N-glycans variables 
(data points) contributing most to the separation observed in the score plots. In red are 
highlighted all the VIP variables with a value >1. The numbers indicated on each plot 
are referred to the code of the peak in the Maldi spectrum. 
 
Then, in order to investigate the effect of aging within the Down syndrome 
disease we compared the DS singletons (DSW) (i.e the subjects unrelated with 
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the DSS group) with the rest of DS subjects, belonging to two different age 
groups but both affected by Down’s syndrome (Pvalue=<0.001). 
Interestingly, the PLS-DA analysis of this aging model within the disease 
showed a clear clustering of the two groups, separated purely on the basis of 
plasma N-glycosylation changes. The overlapping of some samples is given by 
the fact that some subjects of the two groups had a similar age (fig 17). 
 
 PLS-DA: DS vs DSW 
Colored according to classes 
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Figure 17 Scatterplots of the PLS-DA models assessed comparing DS with DSW. 
The plot illustrates the degree of separation between groups.  Each plot represent a 
sample where, in blue are coloured the DS and in yellow the DSW. The triangle 
indicate the males, the square the females. The horizontal scale refers to the first 
component (t[1]), whereas the vertical scale refers to second component (t[2]). 
Lastly, we compared the DS Singletons (DSW) with the group of DSS in order 
to validate the previous models, reducing the number of variables to those that 
should be associated only with the disease or/and aging. In this comparison we 
should have a model that takes into account the effect of disease (because we 
compared DSW with the non affected DSS controls) together with the aging 
effect (because we compared two different age-groups, since that DSW were 
older than DSW) (Fig.18) 
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Figure 18 Scatterplots of the PLS-DA models assessed comparing DS with DSW. 
The plot illustrates the degree of separation between groups.  Each plot represent a 
sample where, in blue are coloured the DS and in yellow the DSW. The triangle 
indicate the males, the square the females. The horizontal scale refers to the first 
component (t[1]), whereas the vertical scale refers to second component (t[2]). 
The variable importance in the projection (VIP) ranks the variables (N-glycans 
identified by m/z values) according to their significance for the model, helping 
to reveal discriminative structures contributing mainly to the separation.  
Therefore, based on the VIP analysis, 67 isotopic peaks of plasma N-glycan 
structures with discriminative potential were extracted, considering in total the 
three PLS-DA models above described (Fig 19). 
In order to understand which variables were exclusive to a N-glycomics 
signature of Down syndrome and what were associated with aging within 
Down syndrome, we have grouped all the 67 VIP variables in an Euler Venn 
diagram, and studied the intersections of the three sets, each representing a 
PLS-DA model (A,B and C)(Fig 19). 
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Figure 19 Description of the three PLS-DA models analyzed with an Euler Venn 
diagram. Each of the three circles/sets includes the VIP variables derived from the 
three PLS-DA models (A,B and C). The blue circle includes all the VIP 
discriminatory variables derived from model A, in which we compared the DS 
subjects with their siblings (DSS) of the same family. The red circle identifies VIP 
variables from the model B, in which we compared the DS singletons (DSW) with the 
rest of the Down subjects (DS). The green circle identifies the VIP variables of model 
C, which represents a validation model of the two previous models, it takes into 
account both disease effect and the aging effect. The arrows indicate the groups of 
variables that have been isolated from the analysis of the intersection of the three 
models/sets. 
 
Interestingly we noticed as the N-glycan species associated with the only effect 
of the disease have been reduced from 37 species to 15 species (derived from 
the models intersection [(A∩C)-B]) and how many of them were influenced by 
the aging effect (see the intersection of the models: A∩B), or by familiarity 
(A\{B∪C}, or other factors that were different from the familiar genetic factors 
(epigenetic factors). 
Subsequently, after having isolated the “N-glycomics signature” of the Down 
syndrome disease from all other confounding effects (aging, familiarity and 
other unknown factors) in order to assess the individual discriminant ability of 
each single component, we applied Wilcoxon Rank sum tests comparing the 
two groups DS versus DSS (Table 3). 
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m/z	  
[M+Na]+	  
Assigned	  
structure	   Composition	   Category	  
R.I	  (%)	  
Median	  	  
(IQR)	  	  	  	  	  	  	  	  	  	  
DS	  
R.I	  (%)	  
Median	  
(IQR)	  
DSS	  
R.I	  (%)	  
Median	  
(IQR)	  
DSM	  
VIP	  
DSvsDSS	   P	  value	   Change	  
Code	  
Peak	  
1282.45	  
	  
H3N3F1	   1	  Fucose,	  Truncated	  
0.15	  
(0.17)	  
0.31	  
(0.33)	  
0.12	  
(0.14)	   1.39	   0.00068	   ! 3	  
1419.48	  
	  
H6N2	   Oligomannosidic	   0.26	  (0.07)	  
0.34	  
(0.10)	  
0.33	  
(0.11)	   1.43	   0.00001	   ! 7	  
1485.53	  
	  
H3N4F1	   1	  Fucose,	  
Truncated	  
2.58	  
(1.40)	  
1.37	  
(1.21)	  
1.94	  
(1.61)	  
1.50	   <0.00001	   " 11	  
1571.53	  
	  
H4N3L1	   Afucosylated	  α	  2-­‐3	  Linkage	  
0.011	  
(0.006)	  
0.017	  
(0.019)	  
0.010	  
(0.007)	   1.27	   0.00032	   ! 15	  
1663.58	   	   H5N4	   Biantennary	  	  
0.13	  
(0.06)	  
0.19	  
(0.08)	  
0.16	  
(0.06)	   1.30	   0.00034	   ! 22	  
1688.61	  
	  
H3N5F1	  
1	  Fucose,	  
Truncated,	  	  
Bisected	  
0.58	  
(0.31)	  
0.33	  
(0.22)	  
0.47	  
(0.34)	  
1.55	   <0.00001	   " 23	  
1850.67	  
	  
H4N5F1	   1	  Fucose,	  Bisected	  
0.85	  
(0.38)	  
0.71	  
(0.36)	  
0.72	  
(0.41)	   1.22	   0.00453	   " 33	  
1936.67	  
	  
H5N4L1	   Afucosylated,	  α	  2-­‐3	  Linkage	  
0.23	  
(0.07)	  
0.30	  
(0.09)	  
0.24	  
(0.06)	   1.63	   <0.00001	   ! 36	  
2447.89	  
	  
H5N4F1E2	   1	  Fucose,	  
α	  2-­‐6	  Linkage	  
4.71	  
(1.55)	  
3.44	  
(1.81)	  
3.10	  
(1.14)	  
1.96	   <0.00001	   " 57	  
2650.97	  
	  
H5N5F1E2	  
1	  Fucose,	  
α	  2-­‐6	  Linkage,	  
Bisected	  
1.81	  
(1.14)	  
1.27	  
(0.95)	  
1.36	  
(0.76)	   1.05	   0.00032	   " 62	  
2894.01	  
	  
H6N5E1L2	   Afucosylated,	  	  α	  2-­‐3	  Linkage	  
0.35	  
(0.16)	  
0.52	  
(0.25)	  
0.46	  
(0.16)	   1.58	   <0.00001	   ! 68	  
2940.05	  
	  
H6N5E2L1	   Afucosylated,	  
α	  2-­‐6	  Linkage	  
2.90	  
(2.00)	  
4.07	  
(1.94)	  
4.12	  
(1.52)	  
1.40	   0.00004	   ! 70	  
3532.23	  
	  
H7N6E1L3	   No	  Fucose,	  	  
α	  2-­‐3	  Linkage	  
0.10	  
(0.07)	  
0.16	  
(0.07)	  
0.11	  
(0.07)	  
1.56	   0.00004	   ! 82	  
3724.33	  
	  
H7N6F1E2L2	   1	  Fucose,	  
α	  2-­‐3	  Linkage	  
0.042	  
(0.03)	  
0.036	  
(0.02)	  
0.033	  
(0.02)	  
1.20	   0.01831	   " 86	  
3770.37	  
	  
H7N6F1E3L1	   1	  Fucose,	  
α	  2-­‐6	  Linkage	  
0.0077	  
(0.008)	  
0.0045	  
(0.005)	  
0.0072	  
(0.007)	  
1.00	   0.00114	   " 87	  
 
Table 3. Discriminators based on multivariate statistical analyses of the PLS/DA, 
assessed comparing Down Syndrome patients (DS) with their non-affected siblings 
(DSS), resulting Plasma carboxy-ethylated N-glycans were analyzed by MALDI-
TOF/MS. Each N-glycan was identified with its m/z and with the corresponding code 
peak of the MALDI-spectum. The median of the percentage of the relative intensity (R.I) 
of each N-glycans structure was calculated for DS and DSS group The arrows are 
indicating a decrease or increase of the relative intensity of the DS respect non-affected 
DSS. The p-values were obtained by a Wilcoxon’s signed rank test after Benjamin-
Hoochberg correction (the significant p-values (<0.05) are highlighted in bold), in order 
to validate the predictive value of the singles variables. Sialylation categories assigned as 
follows: for N-glycans where only α 2-3 or α 2-6 occur then categorization is 
straighforward. When α 2-3≥ α 2-6 then the category is assigned as α 2-3.  
 
52	  	  
All compounds that were considered as potential discriminators have a VIP 
value of 1 or higher for at least two consecutive isotopic peaks. In addition, the 
composition of these structures has been elucidated according the literature or 
MS fragmentation, and each structure was categorized according to its 
chemicals features. In this table, for the qualitative categorization of N-glycans 
carrying sialic acids with both α2,6 and α2,3 glycosidic linkage in their 
terminals galactoses , we considered as α2,3 all those N-glycans having a 
number of α2,3-linked N-acetylneuraminic acids  ≥ α 2-6.  
Interesting, two of the top three discriminators based on the MS data were 
found to be decreased in Down Syndrome patients: the H5N4L1 (m/z 
1936.67[M+Na]+; (VIP value=1.63, Pvalue=<0.00001) as well as the N-glycan 
H5N4E1L1 (m/z 2255.79 [M+Na]+; (VIP value=1.86, Pvalue=<0.00001). 
These peaks identify two bigalactosylated and afucosylated biantennary N-
glycans (G2), respectively, the first is α2-3 mono-sialylated, the second is α2-3 
and α 2-6 sialylated. Instead, the H5N4F1E2 N-glycan (m/z 2255.79 [M+Na]+) 
with the highest VIP value (VIP value=1.96, Pvalue=<0.00001) was found to 
be increased in the DS subjects. This N-glycan is bigalactosylated, core-α-1,6 
fucosylated biantennary, and mono α 2-6 syalylated (G2F). 
Moreover, we observed that in the list of potential discriminators were present 
5 tri-and-tetragalactosylated N-glycan species.  
Furthermore, we observed mainly in these 15 potential discriminators species, 
that when was present one or more fucoses in their structure a significant 
increasing in DS, conversely, the corresponding species without fucose were 
decreased in DS respect DSS. 
In DS, most of these N-glycan species, showed similar values to those of 
mothers or even higher.  
In general, this N-glycomic pattern of disease revealed that fucosylated glycans 
showed a tendency toward increased levels in DS respect non-affected age-
matched controls (DSS).  
Interestingly, we found that 3 structures of this specific pattern, are bisecting 
GlcNAc features. In particular: H3N5F1 (m/z 1688.61); H4N5F1 (m/z 
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1850.67); H4N5E1 (m/z 2023.73); H5N5F1E2 (m/z 2650.97) increased 
significantly in DS respect DSS. 
On the basis of this “N-glycomic signature”, we focused on the general plasma 
N-glycosylation changes that occur in the disease, and we created a set of N-
glycosylation categories, including in analysis all the peaks of total plasma N-
glycome and all subjects affected by Down syndrome (DS+DSW, n=75). 
Moreover, in order to investigate if a premature aging in DS respect to DSS is 
revealed, we included in the analysis also the group of the mothers (DSM), 
representing a control group for age (Table 4) 
N-glycosylation categories included the following glycosylation features: level 
of fucosylation, distinguishing in afucosylated, monofucosylated, and 
structures with more of >1 fucose; level of bisecting; proportion of 
oligomannosidic, truncated and hybrid type glycans; level of sialylation, taking 
into account either alfa 2-3 and alfa 2-6 linkage sialylation. For each feature, 
we summed the relative ion intensities for all glycan peaks presenting that 
feature. 
Truncated structures included all complex N-glycans mono or biantennary 
without galactose (G0) or with one galactose (G1) without a terminal sialic 
acid (NeuNac), that may carry also a core fucose and bisecting GlcNac. The 
level of total alfa 2-3 and total alfa 2-6 linkage sialylation was calculated 
weighting the number of alfa 2-3 or/and alfa 2-6 linked sialic acids on the total 
number of galactoses of each sialylated N-glycan.  
The quantitative analysis of the fucosylation status of the total DS subjects 
revealed a general increasing of fucosylated structures, both in the 
monofucosylated structures than in those with more of one fucose. Instead, the 
afucosylated species decreased in DS respect the non affected subjects. This 
phenomena could be indicate that the fucosylation changes are a peculiar 
aspect of Down Syndrome disease, independently by the aging and gender 
effect (see Table 3 and Fig. 20).   
 
 
 
54	  	  
 
Subjects	   DS	  (n=75)	   DSS	  (n=38)	   DSM	  (n=45)	   Group	  comparison	  
Age	  
	  Mean	  Age,	  ys	  (SD)	   Mean	  Age,	  ys	  (SD)	   Mean	  Age,	  ys	  (SD)	   DS	  vs	  DSS	  P-­‐value	  	  
DS	  vs	  DSM	  
P-­‐value	  	  
32.7	  (14.1)	   30.0	  (12.3)	   56.9	  (9.5)	   0.728872	   <0.000001	  
N-­‐glycosylation	  
category	  	  
R.I	  (%)	  
Median	  (IQR)	  
R.I	  (%)	  
Median	  (IQR)	  
R.I	  (%)	  
Median	  (IQR)	   P-­‐value	   P-­‐value	  
Monofucosylated	  	   28.42	  (7.45)	   24.74	  (5.58)	   22.41	  (4.90)	   0.000179	   <0.000001	  
Fucose	  >1	   0.150	  (0.10)	   0.104	  (0.08)	   0.103	  (0.06)	   0.000486	   0.000002	  
Afucosylated	   71.42	  (7.38)	   75.16	  (5.59)	   77.51	  (4.81)	   0.000138	   <0.000001	  
Bisection	  (H≤N)	   5.55	  (2.18)	   4.86	  (2.04)	   5.08	  (1.72)	   0.003721	   0.073240	  
Oligomannosidic	   1.04	  (0.29)	   1.26	  (0.37)	   1.22	  (0.38)	   0.000006	   0.000044	  
Truncated*	   10.01	  (4.32)	   7.49	  (3.36)	   7.97	  (4.41)	   0.000248	   0.004389	  
Hybrid	  type	   0.401	  (0.14)	   0.457	  (0.15)	   0.406	  (0.11)	   0.008819	   0.810819	  
α	  2-­‐3	  linkage	  (L)	   8.73	  (1.43)	   10.46	  (1.74)	   7.73	  (1.31)	   <0.000001	   0.008727	  
α	  2-­‐6	  linkage	  (E)	   76.81	  (6.11)	   77.11	  (3.43)	   81.14	  (5.35)	   0.883286	   0.016799	  
Subjects	   Male	  DS	  (n=39)	   Male	  DSS	  (n=13)	   Group	  comparison	  
Age	  
Mean	  Age,	  ys	  (SD)	   Mean	  Age,	  ys	  (SD)	   DS	  vs	  DSS	  P-­‐value	  
33.4	  (12.02)	   28.4	  (9.6)	   0.234289	  
N-­‐glycosylation	  
category	  
R.I	  (%)	  
Median	  (IQR)	  
R.I	  (%)	  
Median	  (IQR)	   P-­‐value	  
Monofucosylated	  	   28.98	  (6.59)	   25.37	  (5.48)	   0.007512	  
Fucose	  >1	   0.165	  (0.09)	   0.118	  (0.08)	   0.004785	  
Afucosylated	   70.87	  (6.56)	   74.52	  (5.48)	   0.007052	  
Bisection	  (H≤N)	   5.55	  (1.94)	   4.72	  (1.43)	   0.005820	  
Oligomannosidic	   1.04	  (0.21)	   1.21	  (0.38)	   0.005820	  
Truncated*	   10.33	  (5.20)	   8.00	  (3.14)	   0.025783	  
Hybrid	  type	   0.415	  (0.19)	   0.408	  (0.21)	   0.403870	  
α	  2-­‐3	  linkage	  (L)	   7.24	  (1.16)	   8.48	  (1.36)	   0.000550	  
α	  2-­‐6	  linkage	  (E)	   78.09	  (5.36)	   78.56	  (3.31)	   0.791661	  
Subjects	   Female	  DS	  (n=36)	   Female	  DSS	  (n=27)	   Female	  DSM	  (n=45)	   Group	  comparison	  
Age	  
Mean	  Age,	  ys	  (SD)	   Mean	  Age,	  ys	  (SD)	   Mean	  Age,	  ys	  (SD)	   DS	  vs	  DSS	  P-­‐value	  
DS	  vs	  DSM	  
P-­‐value	  
30.5	  (16.1)	   33.3(13.2)	   56.9	  (9.5)	   0.617364	   <0.000001	  
N-­‐glycosylation	  
category	  
R.I	  (%)	  
Median	  (IQR)	  
R.I	  (%)	  
Median	  (IQR)	  
R.I	  (%)	  
Median	  (IQR)	  
DS	  vs	  DSS	  
P-­‐value	  
DS	  vs	  DSM	  
P-­‐value	  
Monofucosylated	  	   28.12	  (7.21)	   24.44	  (5.46)	   22.41	  (4.90)	   0.025344	   0.000064	  
Fucose	  >1	   0.138	  (0.10)	   0.099	  (0.09)	   0.103	  (0.06)	   0.104377	   0.002740	  
Afucosylated	   71.76	  (7.24)	   75.48	  (5.46)	   77.51	  (4.81)	   0.023581	   0.000062	  
Bisection	  (H≤N)	   5.72	  (2.42)	   5.02	  (2.21)	   5.08	  (1.72)	   0.062728	   0.188855	  
Oligomannosidic	   0.93	  (0.40)	   1.34	  (0.37)	   1.22	  (0.38)	   0.000602	   0.000570	  
Truncated*	   9.79	  (4.30)	   6.89	  (3.39)	   7.97	  (4.41)	   0.013958	   0.124906	  
Hybrid	  type	   0.386	  (0.10)	   	  	  0.469	  (0.18)	   0.406	  (0.11)	   0.000067	   0.290652	  
α	  2-­‐3	  linkage	  (L)	   7.32	  (1.10)	   8.32	  (1.77)	   7.73	  (1.31)	   0.000044	   0.041363	  
α	  2-­‐6	  linkage	  (E)	   80.29	  (6.07)	   79.1	  (3.82)	   81.14	  (5.35)	   0.728424	   0.134199	  
 
Table 4: Multiple comparison between Down patients (DS) with age-matched 
non-affected siblings (DSS) and Mothers  (DSM) for different category of N-
glycans, stratified for sex. For each couple-comparison a non parametric test (Mann-
Whitney test) was assessed with the Benjamini–Hochberg correction. If the FDR-
corrected p-value (q-value) is <=0.05(q-values not reported in the table), the p-values 
are considered significative and highlighted in bold. *In the truncated category we 
have included the asialylated mono or biantennary N-glycans with 0 or 1 galactose 
that may carry core fucose and bisecting GlcNAc 
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Then, we took into account the relative abundance of total bisecting structures 
in DS disease, and we found a significant increase of these species. In 
particular, we found that their concentration is significantly higher compared to 
the age- and sex matched DSS group (P value=0.003721), but not in the 
comparison between DS and DSM (P value=0.073240) (Table 4). 
Fig. 20 Comparison of fucosylation levels in the plasma N-glycome between total DS, 
DSS, and DSM. On the top of the figure are shown the box plots of the relative intensity 
(%) of the N-glycan structures with more one fucose, mono-fucosylated and without 
fucose. At the right the loading plot of the PLS-DA model assessed comparing DS vs DSS, 
where are shown in green the total afucosylated N-glycans, in blue the monofucosyltated, 
and in red and yellow the structures with more of one fucose. 
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Moreover, we investigated if these changes were associated with age. We 
found a strong association between the relative intensity (%) of plasma 
bisection and age (Pvalue=<0.0001), but only in Down subjects (Fig.21).  
Then, stratifying the DS subjects in two age groups (<30 years and >30 years), 
we evidentiated that increasing of bisection  was significant only in the 
subjects with more than of 30 years (Pvalue=<0.001)  both in males and 
females (Fig.22) 
 
Figure 21. A. Box plot of the percentage of relative intensity (R.I %) of plasma bisection 
in the DS, DSS, DSM group, stratified for gender. B. Scatterplot of R.I (%) in function 
of age. 
** 
** 
Figure 22  Bar plot of the percentage of relative intensity of bisection (%) in  
subjects stratified for age groups (<30 and >30 years old) . In A are indicated 
females and in B  males. ** indicate a P-value <0.001. 
** 
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In addition, we took into account the truncated glycan species, in order to study 
all those N-glycans, mono or biantennary with 0 or with 1 galactose without a 
terminal sialic acid (NeuNac), that may carry also a core fucose and bisecting 
GlcNac. Briefly, we focused on the category, so-called, G0 and 
G1(asialylated). As shown in Table 3 and Fig 23, truncated species in DS 
subjects showed a significant increase, compared to both non affected age- and 
sex matched controls (DSS) (Pvalue=0.000248) and mothers group (DSM) 
(Pvalue= 0.004389). Moreover, in DS group, both gender, showed an increase 
in truncated plasma N-glycans compared to age-matched controls DSS 
(Females Pvalue=0.013958; Males P value=0.025783). Interestingly, truncated 
species were also different between DSM and DSS subjects, the decrease took 
on an extreme level in DS subjects while DSM mother showed an intermediate 
value between DSS and DS individuals.  
 
 
 
 
 
Figure	  23 A. Box plot of the percentage of relative intensity (R.I %) of plasma 
truncated N-glycans. in the DS, DSS, DSM group, stratified for gender.	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In addition, as mentioned in materials and methods, we took into account not 
only the total levels of sialylation of human N-glicome. but also the specific 
alfa 2-3 and alfa 2-6 glycosidic linkage of the sialic acids attached to a terminal 
galactose. Interestingly, we found a significant decrease of alfa 2-3 sialylation 
levels in DS compared to the non-affected controls (DSS), both in males and in 
females. However, we observed a trend towards a decrease in alfa 2-3 
sialylation levels from DSS to DSM, with DS subjects, showing intermediate 
values, similar to mother groups (table 3 and fig 24).  
No significant difference was observed in the levels of alpha 2-6 sialylation. 
 
 
 
6. Plasma N-glycome analysis with DSA-FACE technology 
 
As described previously in Material and Method, using DSA-FACE technic we 
detected a set of 10 plasma N-glycans that was chosen for a quantitative 
analysis. Their intensities were normalized to the sum of all those peaks. 
Similarly to the previous analysis performed on MALDI data,  we extracted N-
glycan structures with potential discriminative power, performing a partial lest 
*"**"
**"
Figure	  24	  Box plot of the percentage of relative intensity (R.I %) of plasma alfa 2-
3 and alfa 2-6 linkage sialylation levels. in the DS, DSS, DSM group, stratified 
for gender.	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squares discriminant analysis (PLS-DA)  (see the statistical analysis in 
Materials and Method for details) using as variables for the model the 10 totals 
N-glycans (the variables as gender and age were not considered into the 
analysis).  
The multivariate discriminant analysis performed comparing DS and DSS is 
shown in the PLS-DA scatterplot (Fig 25). 
 
 
The analysis revealed an evident clustering of the two groups, also applying 
this different technological approach in particular a large part of the variation 
within the data (48% R2Ycum) could be explained by the two-component 
PLS-DA model and a good prediction ability was achieved. The corresponding 
loading plot of the PLS-DA model and the variables important in the projection 
(VIP) with a value >1 are shown in fig 26. 
Figure	  25	  Scatterplots of the PLS-DA models assessed comparing DS with DSS. The 
plot illustrates the degree of separation between groups.  Each plot represent a sample 
where, in green are coloured the DS and in red their DSS. The triangle indicate the 
males, the square the females. The horizontal scale refers to the first component (t[1]), 
whereas the vertical scale refers to second component (t[2]).	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Interestingly, we found Peak 1 with the highest VIP value (1.57) , but also 
Peak 3 (1.12) and Peak 4 (1.26).  These last two peaks have the same chemical 
structure, but have a different stereoisomerism about the terminal galactose 
positioned in the branches, and it is interesting as they are placed in a different 
position in the loading plot: peak 3 much more towards the DS group and the 
peak 4 to the DSS group.  
 
 
  
 
 
 
 
Var$ID$(Primary)! VIP[2]!
NGA2F$(1)! 1,57402!
NG1A2F(4)! 1,26534!
NA3(8)! 1,13931!
NG1A2F(3)! 1,1233!
NA2(5)! 1,0861!
Figure	  26 Loading plot of the PLS-DA models assessed comparing DS with DSS. In this 
figure is shown the loading plot of the PLS-DA model based on DSA-FACE data with DS and 
DSS as class identities, which indicates the N-glycans variables (data points) contributing most 
to the separation observed in the score plots. In red are highlighted all the VIP variables with a 
value >1. The numbers indicated on each plot are referred to the code of the peak in the Maldi 
spectrum.	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Based on this first PLS-DA analysis, and in order to deep the discriminatory 
value of GlycoAge test (see introduction for details), which is a variable 
derived from the log ratio between Peak 1 and Peak 6, we performed a second 
PLS-DA analysis, including as additional variables, the glycoAge test, and also 
the ratio between Peak3/Peak 4 (Fig.27). 
This second analysis confirmed the clear clustering of the two groups 
(DSvsDSS) but observing the values of discriminatory VIP variables, we found 
that GlycoAge test had not only the highest VIP value, but it is also  
 
higher compared to Peak 1 individually considered. Moreover, also the ratio 
between peak 3/4 had a high discriminatory power, and its VIP value is higher 
than peak 3.(table 5). 
Looking at the N-glycomics “signature” achieved by using this different 
approach, we noticed how fucosylated species (such as P1, P3) increase in DS 
compared to non-affected controls (both DSM and DSS), and conversely, the 
Figure	  27 Scatterplots of the PLS-DA models assessed comparing DS with DSS, with  
derived variables included. The plot illustrates the degree of separation between groups.  
Each plot represent a sample where, in green are coloured the DS and in red their DSS. 
The triangle indicate the males, the square the females. The horizontal scale refers to the 
first component (t[1]), whereas the vertical scale refers to second component (t[2]).	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species without fucose (such as P5 and P8) decrease.  In addition, the Peak 1 is 
confirmed as a strong discriminator of disease also from the analysis in 
MALDI-TOF. For the other peaks is difficult to confirm the same glycoform in 
either protocols, because the desialylation process before the analysis does not 
allow to take into account the sialylated species. Interestingly, even try-
galactosylate species, similar to the analysis in MALDI-TOF, showed 
significant differences in the disease. This could mean that the N-glycosylation 
changes is not only restricted at the biantennary glycans, more frequently 
present on the plasmatic igG 
 
 
 
Table 5. Discriminators based on multivariate statistical analyses of the PLS/DA, 
assessed comparing Down syndrome patients (DS) with their non-affected 
siblings (DSS). Plasma N-glycans were analyzed by DSA-FACE technology. The 
median of the percentage of the relative aboundance of 10 total peaks, and two 
derivated variables of these peaks (GlycoAge test and the ratio between peak3 and 
peak4) was calculated for DS and DSS group. The arrows are indicating a decrease or 
increase of the relative intensity of the DS respect non-affected DSS. The p-values 
were obtained by a Wilcoxon’s signed rank test after Benjamin-Hoochberg correction 
(the significant p-values are highlighted in bold), in order to validate the predictive 
value of the singles variables.  
 
 
We found that the GlycoAge, evaluated in DS subjects, was similar to that of 
their mothers, chronologically older,  and was significantly higher compared to 
age-matched subjects. This confirmed that the GlycoAge test is able to indicate 
a premature aging in DS. In addition, we found that the ratio between peak 3 
Peak/Variable	   Assigned	  structure	   Composition	  
R.I	  (%)	  
Median	  	  
(IQR)	  	  	  	  	  	  	  	  	  	  
DS	  
R.I	  (%)	  
Median	  
(IQR)	  
DSS	  
R.I	  (%)	  
Median	  
(IQR)	  
DSM	  
VIP	  
DSvsDSS	   P	  value	   Change	  
1	  
	  
H3N4F1	   9.11	  
(2.9)	  
5.58	  
(2.6)	  
7.70	  
(4.2)	  
1.421	   <0.000001	   " 
3	  
	  
H4N4F1	   8.13	  
(2.4)	  
6.46	  
(1.4)	  
6.58	  
(2.6)	  
1.075	   0.000060	   " 
5	  
	  
H5N4	   39.1	  (5.5)	  
42.4	  
(4.3)	  
41.73	  
(6.3)	   1.028	   0.000369	   ! 
8	  
	  
H6N5	   6.11	  
(2.33)	  
	  7.82	  
(2.78)	  
8.16	  
(2.15)	  
1.067	   0.000103	   ! 
GlycoAge	  test	  
	   	  
-­‐0.34	  
(0.17)	  
-­‐0.58	  
(0.23)	  
-­‐0.35	  
(0.30)	   1.468	   <0.000001	   " 
Peak3/Peak4	  
	   	  
0.30	  
(0.12)	  
0.21	  
(0.12)	  
0.20	  
(0.11)	   1.355	   0.000003	   " 
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and peak 4, was able to clearly distinguish the DS from the total not affected 
controls (DSS and DSM), pointing as a marker associated with the disease 
(Fig.27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
** 
** 
** 
** 
Figure 27 Values of GlycoAge test and the ratio between Peak3/4 from 
the three groups of the study (DS-DSM-DSS). The vertical axis represents 
the 95% confidence interval for mean of the percentage of the toal N-glycan 
peak height. 
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Discussion 
 
The glycosylation of proteins is a very complicate and diversified 
phenomenon, due to the intrinsic complexity of the ramified glycan structures. 
In addition, the glycome results to be in a dynamic equilibrium: within an 
individual the glycans pattern remains highly reproducible in a given 
physiological state, but can steadily change in response to altered conditions, 
for example during aging or disease (Ruhaak L, et al, 2010). Therefore, the 
study of protein glycosylation might help identifying potential biomarkers of 
diseases, and contribute to understand their biology/pathogenesis (Pareck et al., 
2006). Recently, the research on human aging, using the modern tools of 
glycomics, has led to the discovery of glycan biomarkers for both longevity 
and aging that may reflect health status and predict the healthy aging 
(Vanhooren V et al., 2007,  Ruhaak L. et al., 2010; Krištić J, et al., 2013). 
It has been hypothesised that these biomarkers could be indicative of the 
biological age of individuals, which do not always correspond to the 
chronological age. It is not yet clear whether this is true or not, therefore we 
addressed the question by studying a model of premature human aging such as 
the Down Syndrome. Down Syndrome subjects (DS) indeed undergo 
premature skin wrinkling and hair greying, visual and hearing impairments, 
thyroid dysfunction, diabetes, obesity, immune senescence and Alzheimer-like 
dementia (Esbensen, 2010). We thus reasoned that, if the age-related changes 
of the glycome should be present also in relatively young DS, this could be a 
demonstration that these markers are indicative of the biological age of the 
individuals; on the contrary if no difference is found with non trisomic age-
matched subjects, this could indicate that these markers are related to the pure 
chronological age. Finally, it is also possible that Down syndrome per se is 
characterised by a glycomic signature with respect to non trisomic subjects. 
Therefore, the research project was aimed at studying DS subjects from a 
glycomic point of view by using the most advanced techniques available at 
present. 
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There are several approaches to glycosylation analysis, all of which have their 
strengths and limitations, including mass spectrometry (MS), high performance 
liquid chromatography (HPLC), capillary electrophoresis (CE) and lectin 
binding (Arnold, J.N et al.,2004). MS and HPLC analysis of sugars released 
are very sensitive methods of analysis of glycans , and can give all the 
structural information. Lectin can be easily incorporated in tests based on 
ELISA, but these reagents generally have a low specificity and affinity for 
glycan epitopes and can not be used to provide a complete structural analysis. 
The identification and validation of new biomarkers requires detailed analysis 
of glycans, quantitative and sensitive. Currently these requirements are best 
met by a combination of HPLC and/or MS (Arnold, J.N et al.,2008). Recently, 
the Gent University developed a quantitative N-glycan analysis system based 
on DSA-FACE, that is a robust, reproducible and high-throughput technology 
platform. However, this technique has a limitation as it works on desialylated 
N-glycans, thus misses information about the sialic acid distribution 
(Vanhooren et al, 2008). 
To overcome this limitation, a new protocol based on MALDI-TOF mass 
spectrometry was developed by the LUMC Glycomics and Glycoproteomic 
Laboratory (Reiding K, et al, 2013, submitted), that is sensitive and 
quantitative and it can be used to analyse 112 N-glycans identified in human 
plasma, and it is able to analyse the specific alfa 2,3 and alfa 2,6 glycosidic 
linkage of sialic acids. In this study we applied both methods to our samples. 
 
We focused on N-glycosylation changes of plasma proteins that occur in Down 
syndrome subjects, as mentioned, and in particular we studied a familiar model 
of disease, composed by: i) DS subjects (DS); ii) their age matched siblings 
(DSS). At the same time we investigated if N-glycans were able to predict a 
premature aging on DS, comparing DS with their mothers (DSM) i.e subjects 
of different chronological age and with a similar genetic background. This 
familiar model allowed us to minimize the effects of genetic individual 
variability and environment. 
66	  	  
 
The analysis in mass spectrometry revealed that Down syndrome impacts 
significantly on the N-glycosylation changes of plasma proteins, generating a 
characteristic “signature” of disease. In particular, we identified by comparing 
the DS with their age- and sex matched siblings, 37 glycan species that 
changed significantly in the two groups. 
The analysis was further deepened considering which of these N-glycan 
species were influenced by the effect of age. This was achieved by comparing 
DS subjects of different ages. The analysis led to the identification that 16 N-
glycan species changed during aging of subjects affected by disease. Finally, 
the comparison between DS unrelated with non-affected controls allowed us to 
further refine the signature of the syndrome by excluding 7 species (that could 
indicate a individual/familial contribution) from the original pool of 37 glycans 
associated with DS. From these analyses we have, therefore, identified the final 
N-glicomics signature of disease consisting of 15 N-glycans species.  
 
Within this N-glicomic signature, we identified, H3N4F1, an agalactosyl (G0) 
N-glycan, corresponding to the “Peak1” of DSA-FACE fingerprinting, which 
we found, in our previous studies, to be increased with age. Interestingly, the 
relative abundance of this N-glycan resulted not only increased compared to 
DSS, but also to DSM, who are chronologically older than DS.  Most of this N-
glycan species had similar values to those of DSM or even higher, in 
agreement with the hypothesis that Down syndrome, also from the point of 
view of glycomics, shows the characteristics of a premature aging. 
Among them appears also H5N4F1E2, a core-fucosylated biantennary (G2) 
and alpha 2-6 sialylated N-glican, which should be included in the G2 N-
glycans pool, grouped by “Peak 6,” through analysis in the DSA-FACE. 
Interestingly, we found in DS a significant increase of this N-glycan compared 
to DSS and DSM. Generally, our previous studies demonstrated a decrease of 
this glycan with age.   
Looking at the N-glycan signature we noticed that in DS a general increase of 
fucosylation occurs, since many of the glycan species were fucosylated, while 
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the non fucosylated decreased; moreover, all those afucosylated species were 
also galactosylated. 
We therefore wanted to investigate the mechanisms that underlie the N-
glycosylation changes, and we created some N-glycans categories, which take 
into account all detectable plasma N-glycans, grouped in order to share the 
same chemical characteristic.  
Therefore, we took into account the fucosylation process, discriminating 
between monofucosylated, polyfucosylated and afucosylated. The species with 
more than one fucose could give an indication of the fucosylation process of 
antennae, as for sure a fucose is localized in the core and the other in the 
antennae. 
This analysis confirmed our hypothesis that all fucosylated species are more 
expressed in DS, and fucosylation affects both biantennary and tri and tetra 
antennary species.  
 
The presence or absence of fucose within the glycan chains is strongly related 
to autoimmune diseases and cancer. Moreover, when linked to the NAcGlc and 
a sialic acid alfa 2-3 linked  fucose forms a specific chain, defined Sialyl Lewis 
x(sLex). sLex is present on numerous proteins, in cases of acute and chronic 
inflammation (Van Dijk W. et al. Glycoconj. J. 1995). 
The expression of this chain counteracts the progression of pathologies; it has 
been observed in fact, that treatments with soluble sLex may counteract the 
inflammation-induced tissue damage (Mulligan MS. Et al., Nature 1993). 
Moreover, in vitro studies have shown that during short-term acute 
inflammation, alfa1-acid glycoprotein contains increased biantennary 
structures, but this shifts to an increase in tri- and tetra-antennary structures 
with long term chronic inflammation (De Graaf, T et al, 1993; Fassbender, K et 
al, 1991). 
Increased tri and tetra-antennary glycans with SLex attached to haptoglobin 
have been reported in chronic inflammatory conditions such as alcoholic liver 
disease (Grevel, P. et al.; 1996), rheumatoid arthritis (RA) (Thompson, S.,et 
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al., 1993), ovarian cancer, stomach cancer and Crohn’s disease (Goodarzi, M.T 
et al., 1998). 
The increase in tri and tetra-antennary glycans and Slex in the serum may 
reflect a systemic side effect of the inflammatory cytokines on the hepatocytes 
of the liver (Arnolod J.N et al, 2008). 
Therefore, the increase in fucosylation that we have found in individuals with 
Down syndrome might be related to a higher abundance of these sLex 
structures, which would feed a state characteristic of chronic inflammation, 
involving multiple mechanisms, both  hepatic and  immunological.  
 
Unlike the biantennary truncated species, (like GO and the asialylated G1), we 
found an increase of these species in DS compared to age matched controls, 
and they reached similar values (mainly in females) to their mothers or even 
more elevated. 
In literature, IgG-G0 are elevated in cancer patients and have been shown to 
increase with tumour progression. Hyperfucosylation has also been identified, 
and this is a result of an increase in the glycan structure F(6)A2, which forms 
part of IgG-G0 glycoform population. F(6)A2 in the serum is almost 
exclusively attached to IgG molecules, and a small proportion is present on 
IgA (Comunale, M.A et al, 2006, Arnolod J.N 2008). The serum increase in 
IgG-G0 has classically been described in relation to the chronic inflammatory 
condition, RA, however serum elevations of IgG-G0 are also found in other 
inflammatory chronic conditions such as Crohn’s disease, juvenile onset 
chronic arthritis, systemic lupus erythematosus complicated by Sjögren’s 
syndrome and tuberculosis (Parekh et al, 1985; Bond, A,: 1997). 
IgG-G0 can also be considered to be a pro-inflammatory molecule since the G0 
glycans are epitopes for lectin binding (Dong, X, et al, 1999; Malhotra, R, et al, 
1995) and activate the complement cascade. 
 
A relationship between agalactosylated G0/and less sialylated igG, with 
“inflammaging” i.e the low-grade pro inflammatory status that characterizes 
elderly (Franceschi C, et al,. 2000), has been conceptualized in a recent review 
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by our group (Dall’Olio F et al, 2012). The Down Syndrome could have an 
higher grade of “inflammaging”, respect the non affected subjects, and the 
concentration of GO could be an efficient marker of inflammaging. 
 
Finally, the N-glycome profiling performed with the DSA-FACE technology 
has shown to be sensitive enough to distinguish the DS from DSS. We have 
found, similarly to the analysis in MALDI TOF, that the peak 1 is able to 
discriminate between DS and non affected controls, reaching the highest values 
in DS.  Also the DSA-FACE profiling, indicated that afucosylated and 
galactosylated peak decreased in DS, and the fucosylated species decreased, as 
the peak 1 and 3. 
Moreover, we found that the GlycoAge, evaluated in DS subjects, was similar 
to that of their mothers, chronologically older,  and was significantly higher 
compared to age-matched subjects. This confirms that the GlycoAge test is 
able to indicate a premature aging in DS. In addition, we found that the 
relationship between peak 3 and peak 4, is able to clearly distinguish the DS 
from the non affected controls (DSS and DSM), pointing as a marker 
associated with the syndrome. 
 
Further studies will be needed to clarify the precise role of these N-glycans in 
the aging process of the immune system and of the organism as a whole, 
especially in the context of the Down syndrome that has been tackled in this 
study. 
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